[('The GWAS genotyping of the Spanish SSc and controls together with Dutch and German SSc patients was performed at the Department of Medical Genetics of the University Medical Center Utrecht (The Netherlands) using the commercial release Illumina human CNV370K BeadChip that contains 300.000 standard SNPs with an additional 52,167 markers designed to specifically target nearly 14,000 copy number variant (CNV) regions of the genome, for a total of over 370,000 markers.', {'entities': [(236, 244, 'platform')]}),
 (' Genotype data for Dutch and German controls was obtained from the Illumina Human 550K BeadChip available from a previous study _, .', {'entities': [(67, 75, 'platform')]}),
 (' The North American SSc patient group was genotyped at Boas Center for Genomics and Human Genetics, Feinstein Institute for Medical Research, North Shore LIJ Health System, using the Illumina Human610-Quad BeadChip capturing 89% of the HapMap CEU variation at r_2  > 0.8.', {'entities': [(183, 191, 'platform')]}),
 (' Genotype data were then assessed using the Genotyping Module of Illumina’s BeadStudio software (version 2.0).', {'entities': [(65, 73, 'platform')]}),
 ('We genotyped cases in the first phase of the study on the Illumina 370K chip.', {'entities': [(58, 66, 'platform')]}),
 (' We utilized controls from the 1958 Birth Cohort that had been previously genotyped on the Illumina 550K chip.', {'entities': [(91, 99, 'platform')]}),
 (" Genotype calls were made using the auto-calling algorithm in Illumina's BeadStudio 2.0 software.", {'entities': [(62, 70, 'platform')]}),
 (" Genotype clusters were determined using Illumina's BeadStudio 2.0 software after first eliminating 240 samples (9.", {'entities': [(41, 49, 'platform')]}),
 ('Genotype reports produced by Illumina BeadStudio 2.0 software (stage I data) or SEQUENOM Typer 4.', {'entities': [(29, 37, 'platform')]}),
 ('Genome-wide genotyping was performed using Illumina Human Hap550K chips.', {'entities': [(43, 51, 'platform')]}),
 (' Of these, 199 were represented on the Illumina HumanHap 550K genotyping chip either directly or via a proxy with an r_2  greater than 0.8.', {'entities': [(39, 47, 'platform')]}),
 (' Allele cluster definitions for each SNP were determined using Illumina BeadStudio Genotyping Module version 3.1.', {'entities': [(63, 71, 'platform')]}),
 (' Allele cluster definitions for each SNP were determined using Illumina BeadStudio Genotyping Module version 3.1.', {'entities': [(63, 71, 'platform')]}),
 ('  All subjects from the Family Heart Study were genotyped on the Illumina HumMap 550 chip.', {'entities': [(65, 73, 'platform')]}),
 ('  Genotyping was performed using the Illumina 370CNV BeadChip system on 3,980 Cardiovascular Health Study (CHS) participants who were free of cardiovascular disease at baseline.', {'entities': [(37, 45, 'platform')]}),
 ('  Individuals were genotyped on the Illumina Human610 Genotyping Beadchip (, ).', {'entities': [(36, 44, 'platform')]}),
 (' All subjects from the Family Heart Study were genotyped on the Illumina HumMap 550 chip.', {'entities': [(64, 72, 'platform')]}),
 (' Genotyping was performed using the Illumina 370CNV BeadChip system on 3,980 Cardiovascular Health Study (CHS) participants who were free of cardiovascular disease at baseline.', {'entities': [(36, 44, 'platform')]}),
 (' Individuals were genotyped on the Illumina Human610 Genotyping Beadchip (, ).', {'entities': [(35, 43, 'platform')]}),
 (' Samples (399) were genotyped using the Illumina HapMap550K.', {'entities': [(40, 48, 'platform')]}),
 ('Pedigrees members of the GAIT study were typed with the Illumina Infinium 317 Beadchip as previously described.', {'entities': [(56, 64, 'platform')]}),
 (' Persons for the initial GWAS analysis on VT were typed with the Illumina Sentrix HumanHap300 Beadchip with genotyping quality control criteria previously described.', {'entities': [(65, 73, 'platform')]}),
 (' Monocytes RNA profiles were generated using Illumina Human HT-12 expression V3 BeadChips.', {'entities': [(45, 53, 'platform')]}),
 (' In the genomewide association study, we determined the genotypes of patients with vitiligo for approximately 610,000 markers by using the Illumina 610-Quad BeadChip.', {'entities': [(139, 147, 'platform')]}),
 (' The MSA1 plate was fragmented with FMS reagent (Illumina) at 37 °C for 1 h, precipitated with 2-propanol, and incubated at 4 °C for 30 min.', {'entities': [(49, 57, 'platform')]}),
 (' The resulting blue precipitate was resuspended in RA1 reagent (Illumina) at 48 °C for 1 h.', {'entities': [(64, 72, 'platform')]}),
 (' The Illumina BeadStudio 3.2 software was used to generate SNP genotypes from bead intensity data.', {'entities': [(5, 13, 'platform')]}),
 ('  The original genotype data contained 620,903 markers, including 620,901 genomic markers on the Illumina chip plus 2 APOE SNPs whose values were obtained from the APOE status data.', {'entities': [(97, 105, 'platform')]}),
 (' The original genotype data contained 620,903 markers, including 620,901 genomic markers on the Illumina chip plus 2 APOE SNPs whose values were obtained from the APOE status data.', {'entities': [(96, 104, 'platform')]}),
 (' The whole genome genotyping was conducted using the Illumina Veracode platform and 610-Quad high throughput genotyping chips.', {'entities': [(53, 61, 'platform')]}),
 (' Genotyping within EPAS1  was conducted using a customer-designed Illumina GoldenGate assay (384 SNP plex) for all samples from Mag Xiang and some of the samples from Zhaxizong Xiang.', {'entities': [(66, 74, 'platform')]}),
 (' The whole genome genotyping was conducted using the Illumina Veracode platform and 610-Quad high throughput genotyping chips.', {'entities': [(53, 61, 'platform')]}),
 (' Genotyping within EPAS1  was conducted using a customer-designed Illumina GoldenGate assay (384 SNP plex) for all samples from Mag Xiang and some of the samples from Zhaxizong Xiang.', {'entities': [(66, 74, 'platform')]}),
 ('  Genotyping information for rs872071 was taken from the Illumina 317K data generated for the GWAS.', {'entities': [(57, 65, 'platform')]}),
 (' Genotyping information for rs872071 was taken from the Illumina 317K data generated for the GWAS.', {'entities': [(56, 64, 'platform')]}),
 ('  The melanoma analysis of rs872071 was conducted within the GenoMEL GWAS data set; rs872071 is on the Illumina 317K array.', {'entities': [(103, 111, 'platform')]}),
 (' The analysis of rs872071 involved genotyping information taken from the Illumina 317K array utilized in the GenoMEL GWAS.', {'entities': [(73, 81, 'platform')]}),
 (' The melanoma analysis of rs872071 was conducted within the GenoMEL GWAS data set; rs872071 is on the Illumina 317K array.', {'entities': [(102, 110, 'platform')]}),
 (' The analysis of rs872071 involved genotyping information taken from the Illumina 317K array utilized in the GenoMEL GWAS.', {'entities': [(73, 81, 'platform')]}),
 (' The MSA1 plate was then fragmented with FMS reagent (Illumina) at 37 °C for 1 h and then precipitated with 2-propanol and incubated at 4 °C for 30 min.', {'entities': [(54, 62, 'platform')]}),
 (' The resulting blue precipitate was then resuspended in RA1 reagent (Illumina) at 48 °C for 1 h.', {'entities': [(69, 77, 'platform')]}),
 ('We genotyped the DNA samples of the CSSCD and Duke subjects with the Illumina Human610-Quad SNP array that includes more than 600,000 SNPs and covers ~60% of the genome of the HapMap Yoruban (r _2  > 0.8) and 18,000 known genes.', {'entities': [(69, 77, 'platform')]}),
 (' We genotyped the DNA samples from the BMC patients in an earlier phase of the study, with the Illumina HumanCNV370-duo bead chip that comprises ~350,000 SNPs common to the 610 array.', {'entities': [(95, 103, 'platform')]}),
 (' We used a BF >3 to select significant SNPs in genes based on the following consideration: The mean number of SNPs per gene in the Illumina 610 is 25, and because the decision rule to accept an association as significant if the BF >3 has a false positive rate of about 2%, the expected number of false positive single SNP association per gene is on average 5%.', {'entities': [(131, 139, 'platform')]}),
 (' All cases were genotyped with the Illumina Human 610Quad platform.', {'entities': [(35, 43, 'platform')]}),
 (' Controls were genotyped with the Illumina 370Duo platform.', {'entities': [(34, 42, 'platform')]}),
 (' All cases were genotyped with the Illumina Human 610Quad platform.', {'entities': [(35, 43, 'platform')]}),
 (' Controls were genotyped with the Illumina 370Duo platform.', {'entities': [(34, 42, 'platform')]}),
 (" Samples that passed the above exclusion criteria were genotyped using Illumina's Human 1Mv1 Beadchip, containing 1,072,820 SNPs (of those 258,665 loci are in reported and new CNV regions).", {'entities': [(71, 79, 'platform')]}),
 (' Illumina provides information on which 1M BeadChip SNPs were located within known common CNV-regions.', {'entities': [(1, 9, 'platform')]}),
 ('Cases were ascertained through the National Alopecia Areata Registry (NAAR) with approval from institutional review boards and genotyped on the Illumina HumanHap 610 chip.', {'entities': [(144, 152, 'platform')]}),
 (' These had been genotyped on the Illumina HumanHap 550v2. All samples were confirmed to be of European ancestry by principal component analysis with ancestry informative markers.', {'entities': [(33, 41, 'platform')]}),
 ('Briefly, this study reports the follow-up genotyping of studies based on the previously reported genome-wide scan conducted in the prospective Nurses’ Health Study using the Human Hap500 Infinium Assay (Illumina) in 1,145 cases of women with post-menopausal breast cancer and 1,142 controls .', {'entities': [(203, 211, 'platform')]}),
 (' Stage 2 was genotyped using a custom-designed iSelect assay from Illumina with content described above; 9,804 samples were attempted (including known duplicates).', {'entities': [(66, 74, 'platform')]}),
 (' All subjects were genotyped using the Illumina HumanHap550 BeadChip with over 550,000 single nucleotide polymorphism (SNP) markers.', {'entities': [(39, 47, 'platform')]}),
 ('1 locus, we examined the association statistics for these markers in a third independently generated and analysed cohort, including 1,390 subjects from 447 autism families genotyped with ~1 million markers on the Illumina HumanHap1M BeadChip (CAP cohort, ).', {'entities': [(213, 221, 'platform')]}),
 (' To seek further evidence of replication, we examined association statistics from a fourth independent cohort of 108 ASD cases and 540 genetically matched control subjects, genotyped on the Illumina HumanCNV370 BeadChip, an array with over 300,000 SNP markers (CART cohort, ).', {'entities': [(190, 198, 'platform')]}),
 ("All genome-wide SNP genotyping for the discovery cohorts was performed using the Illumina HumanHap550 BeadChip at the Center for Applied Genomics at the Children's Hospital of Philadelphia.", {'entities': [(81, 89, 'platform')]}),
 (' A total of 331918 SNPs (common in both the Illumina HumanHap 370k and 610k BeadChips) of 377 case-control pairs were used in the analysis.', {'entities': [(44, 52, 'platform')]}),
 (' Genotyping data for the top 44 SNPs were obtained from the Illumina HumanHap 660k and 610k BeadChips in the MDACC study.', {'entities': [(60, 68, 'platform')]}),
 (' In the Harvard study, genotyping was done with the Illumina Human610-Quad BeadChip.', {'entities': [(52, 60, 'platform')]}),
 ('5 μg of genomic DNA (15 μl of 100 ng/μl stock) and Illumina Infinium II HumanHap 300 BeadChips and assay protocol [].', {'entities': [(51, 59, 'platform')]}),
 (' Genotypes with GenCall (Illumina) scores less than 0.15 were set to missing (0.', {'entities': [(25, 33, 'platform')]}),
 (' The Illumina 370CNV BeadChip array was genotyped on 3664 participants.', {'entities': [(5, 13, 'platform')]}),
 (' The Illumina 370CNV BeadChip array was genotyped on 3664 participants.', {'entities': [(5, 13, 'platform')]}),
 ('DNA from all of the LCLs was genotyped using Illumina HumanHap 550K and 510S BeadChips, which assayed 561,298 and 493,750 SNPs, respectively.', {'entities': [(45, 53, 'platform')]}),
 (' The genotyping data from 166 of 277 LCLs using Illumina HumanHap 550K BeadChips had been used in a previous study ().', {'entities': [(48, 56, 'platform')]}),
 (' Genotyping was undertaken using Illumina HumanHap 550K SNP chips and full phenotype and raw genotyping data are available at https://queue.', {'entities': [(33, 41, 'platform')]}),
 (' This cohort was genotyped using the Illumina HumanHap 300K platform.', {'entities': [(37, 45, 'platform')]}),
 (' To facilitate confirmation of strand and direction between the Illumina and KASPar genotyping assays, we also genotyped 27 SNPs in 10 replicate individuals from the Irish genome scan using the KASPar platform.', {'entities': [(64, 72, 'platform')]}),
 (' The genotyping concordance rate between the Illumina and KASPar assays was 99.3%, with the non-concordant calls being accounted for by two failed assays on the KASPar platform.', {'entities': [(45, 53, 'platform')]}),
 (' The DNA for 1458 subjects was genotyped using Illumina (San Diego, CA, USA) genotyping chips and single-nucleotide polymorphisms (SNPs) from the HumanH610 were used for analysis (Supplementary methods).', {'entities': [(47, 55, 'platform')]}),
 (' Select polymorphisms from earlier studies of cognition were analyzed if present on the Illumina HumanHap610 or tagged with an r _2  above 0.8 on the chip ().', {'entities': [(88, 96, 'platform')]}),
 (" Illumina's BeadStudio3.1.", {'entities': [(1, 9, 'platform')]}),
 (' A subset of these records is linked to eMERGE-supported Illumina 660W-Quad genotyping, and the results of the PR analysis are presented here.', {'entities': [(57, 65, 'platform')]}),
 ('Genotyping was performed at the Center for Genotyping and Analysis at the Broad Institute, using the Illumina Human660W-Quadv1_A genotyping platform, consisting of 561,490 SNPs and 95,876 intensity-only probes.', {'entities': [(101, 109, 'platform')]}),
 ("Samples were genotyped using the Illumina HumanCytoSNP-12™ array utilizing Infinium® HD Assay Ultra genotyping assay methods (∼300,000 single nucleotide polymorphisms (SNPs)) according to the manufacturer's instructions at the genotyping facilities located at OMRF (Oklahoma City, OK).", {'entities': [(33, 41, 'platform')]}),
 ('5) patients with idiopathic biopsy-proven FSGS and no family history of FSGS using the Illumina 1M-Duo platform.', {'entities': [(87, 95, 'platform')]}),
 (' We used 1641 unselected European American samples and 1827 unselected African American samples genotyped with the Illumina 550Kv3 platform from the iControldb database (http://www.', {'entities': [(115, 123, 'platform')]}),
 (' Strand issues were not a concern, because C/G or A/T SNPs are not genotyped in the Illumina 550Kv3 platform — these polymorphisms can give rise to spurious case-control comparisons when other genotyping platforms are used, a frequent cause of problems if the data describing which strand is used to code the SNPs is incorrect or unavailable.', {'entities': [(84, 92, 'platform')]}),
 (' We approximated the ancestral frequencies of the two populations using the Illumina controls cohort in the following way: \n pE(t)∼p′E(t)pA(t)∼p′B(t)−mp′E(t)1−m  This method of estimating the two allele frequencies is conceptually much simpler than the one described in [], which uses a Markov chain Monte Carlo approach to estimate the frequencies both from cases and controls.', {'entities': [(76, 84, 'platform')]}),
 ('Nine hundred and fourteen individuals were genotyped for 318,127 autosomal and X-chromosomal SNPs with the Illumina Sentrix HumanHap300 BeadChip; genotypes were automatically called using the proprietary BeadStudio software.', {'entities': [(107, 115, 'platform')]}),
 (' Control genotypes for 5069 individuals (from the 1958 British Birth Cohort and UK Blood Service) were determined using a custom Illumina 1.2M Beadchip (www.', {'entities': [(129, 137, 'platform')]}),
 (' Data for four studies were available from a genome wide scan using the same Illumina Infinium 610K array that was used in Phase 1 excluding samples with call rate <95%, >1% discordance, <80% European ancestry, or ambiguous gender.', {'entities': [(77, 85, 'platform')]}),
 (' For one study, Illumina Infinium 317K data were used with imputation based on HapMap CEU data following 100 iterations in MACH version 1.0.', {'entities': [(16, 24, 'platform')]}),
 ('5% HapMap mismatch), and additional control data used the Illumina Infinium 317K and HumanCNV370-duo Bead Arrays; per-SNP call rate was >97%, and concordance was >98.5%.', {'entities': [(58, 66, 'platform')]}),
 ('Genotyping for the discovery set was performed using the Illumina HumanHap610 chip.', {'entities': [(57, 65, 'platform')]}),
 (" Genotyping for the replication phase 1 series was obtained from GWAS of lung cancer risk using Illumina's HumanHap300 BeadChip ().", {'entities': [(96, 104, 'platform')]}),
 (' The MSA1 plate was fragmented with FMS reagent (Illumina) at 37°C for 1 hour, precipitated with 2-propanol, and incubated at 4°C for 30 minutes.', {'entities': [(49, 57, 'platform')]}),
 (' The resulting blue precipitate was resuspended in RA1 reagent (Illumina) at 48°C for 1 hour.', {'entities': [(64, 72, 'platform')]}),
 (' The Illumina BeadStudio 3.2 software was used to generate SNP genotypes from bead intensity data.', {'entities': [(5, 13, 'platform')]}),
 ('0 [ARIC], 500K and 50K gene-centric [FHS]) or Illumina (Human CNV370 [AGES, CHS], 550K [RS], HumanHap300 Duo-Plus or a combination of HumanHap300 and iSelect [WGHS]).', {'entities': [(46, 54, 'platform')]}),
 (' All DNA samples for the Illumina Infinium 370cnvDuo array were prepared for genotyping by the Broad Institute Biological Sample Repository (BSP) as a part of STAMPEED consortium funded by the US National Heart, Lung, and Blood Institute.', {'entities': [(25, 33, 'platform')]}),
 (' All EUROSPAN cohorts were genotyped using Illumina 317K platform.', {'entities': [(43, 51, 'platform')]}),
 (' All DNA samples for the Illumina Infinium 370cnvDuo array were prepared for genotyping by the Broad Institute Biological Sample Repository (BSP) as a part of STAMPEED consortium funded by the US National Heart, Lung, and Blood Institute.', {'entities': [(25, 33, 'platform')]}),
 (' All EUROSPAN cohorts were genotyped using Illumina 317K platform.', {'entities': [(43, 51, 'platform')]}),
 (' All DNA samples for the Illumina Infinium 370cnvDuo array were prepared for genotyping by the Broad Institute Biological Sample Repository (BSP).', {'entities': [(25, 33, 'platform')]}),
 (' Genotyping of Rotterdam subjects was conducted with the Illumina HumanHap550K array on 5974 participants.', {'entities': [(57, 65, 'platform')]}),
 (' AGES-Reykjavik genotyping was conducted with the Illumina 370CNV BeadChip array on 3664 participants.', {'entities': [(50, 58, 'platform')]}),
 (' Standard Illumina protocols were followed, requiring SNP clustering scores greater than 0.4.', {'entities': [(10, 18, 'platform')]}),
 ('0 × 10_−9 , position mismatches across databases (Illumina, dbSNP and/or HapMap) and call rate <97%.', {'entities': [(50, 58, 'platform')]}),
 (' We retained data from 315,860 SNPs from Illumina analysis that had genotyping results in 90% or more subjects, but 410 were monomorphic for analysis in individuals of European descent (and hence not informative).', {'entities': [(41, 49, 'platform')]}),
 (' Biotinylated cRNA was applied to Illumina HumanWG-6 v1 Expression BeadChips and hybridized overnight at 58°C.', {'entities': [(34, 42, 'platform')]}),
 (' The probe detection level was assessed with the use of Illumina’s detection P  value, where at least 18 of the 35 samples were required to have a detection of P  less than .', {'entities': [(56, 64, 'platform')]}),
 (' For the Illumina Infinium platform, in addition to the four CEPH controls included in each 96-well plate provided by the genotyping service provider, 15 out of 585 samples were genotyped twice.', {'entities': [(9, 17, 'platform')]}),
 (' For the Illumina Infinium platform, in addition to the four CEPH controls included in each 96-well plate provided by the genotyping service provider, 15 out of 585 samples were genotyped twice.', {'entities': [(9, 17, 'platform')]}),
 ('For Illumina BeadChip genotyping, preliminary SNP quality control was assessed by the genotyping service provider, including call frequency (< 0.98), cluster separation (< 0.', {'entities': [(4, 12, 'platform')]}),
 (' Genotyping of a genome-wide set of 307\u2009984 SNPs was performed using the Illumina Infinium 317k Beadchip.', {'entities': [(73, 81, 'platform')]}),
 (' Genotyping was performed using the Illumina Infinium II Human 1M Beadchip.', {'entities': [(36, 44, 'platform')]}),
 (' As described elsewhere, DNA extracted from the baseline WGHS blood samples underwent SNP genotyping using the Illumina Infinium II assay to query a genomewide set of 318,237 SNP markers (Human HAP300 panel) as well as an additional focused panel of 45,751 SNPs selected to enhance coverage of genomic regions without regard to allele frequency in which we had a strong a priori interest owing to presence of genes thought to be of relevance to metabolic, lipid, inflammatory, and other biological functions.', {'entities': [(111, 119, 'platform')]}),
 (' The genotype data derive from Illumina Human HAP300 genotyping among 670 PRINCE participants, of whom 168 (25.1%) were female.', {'entities': [(31, 39, 'platform')]}),
 ('Nine hundred and seventy-two case samples, including 841 self-identifying as ‘white’, were genotyped on the Illumina HumanHap 650Y product at Rosetta Inpharmatics.', {'entities': [(108, 116, 'platform')]}),
 (' All samples were of self-reported causasian ancestry and genotyped on the Illumina HumanHap 550Y product.', {'entities': [(75, 83, 'platform')]}),
 (' The first phase involved genotyping through ServiceXS in Leiden, The Netherlands, using the Illumina HumanHap300 BeadChip version 2 duo array (with 317k tagging SNPs).', {'entities': [(93, 101, 'platform')]}),
 (' Subsequent genotyping of cases was conducted at CNG in Paris using the Illumina Humancnv370k array.', {'entities': [(72, 80, 'platform')]}),
 (' Genotyping of a genome-wide set of 1,054,559 SNPs was performed using the Illumina Infinium II Human 1M bead chip at two national centres (Centre National de Génotypage, Paris, France and the SNP Technology Platform, Uppsala, Sweden).', {'entities': [(75, 83, 'platform')]}),
 ('Genotyping for stage 3 was conducted using a custom-designed Illumina iSelect array, as part of the replication phase 2 of CGEMS.', {'entities': [(61, 69, 'platform')]}),
 (' Data on the NHS were taken from their GWAS, conducted using an Illumina Infinium 550k array (these data were included in stage 4 since they were not used in the analysis of stage 3 and the selection of the three SNPs for stage 4).', {'entities': [(64, 72, 'platform')]}),
 (' DNA extracted from the baseline blood samples underwent SNP genotyping using the Illumina Infinium II assay to query a genome-wide set of 315,176 haplotype-tagging SNP markers (Human HAP300 panel) as well as a focused panel of 45,882 missense and haplotype tagging SNPs selected to enhance coverage of genomic regions in which we had a strong a priori  interest owing to presence of genes believed to be of relevance to metabolic, cardiovascular, and inflammatory diseases.', {'entities': [(82, 90, 'platform')]}),
 (' We also compared the Illumina-based SNP data for each individual participant for a panel of 44 common SNPs that have previously been ascertained in this population using alternative genotyping technologies; this step is used as a secondary check to ensure accurate specimen labeling prior to any analyses.', {'entities': [(22, 30, 'platform')]}),
 (' We genotyped stage 2 replication samples with (i) the Illumina 317K array at the Feinstein Institute (for the NARAC-III samples; unpublished data); (ii) using the kinetic PCR platform at Celera Diagnostics (for the GCI and LUMC samples); and (iii) with the Sequenom iPlex platform at the Broad Institute (for the EIRA-II and AMC/UVA samples).', {'entities': [(55, 63, 'platform')]}),
 (' Finally for the NARAC-III cases (unpublished data) and shared controls, we used available Illumina 317K GWA data for 269,771 SNPs passing stringent quality control criteria.', {'entities': [(91, 99, 'platform')]}),
 (' Samples were processed according to the Illumina Infinium 2 assay manual.', {'entities': [(41, 49, 'platform')]}),
 (' Normalized bead intensity data obtained for each sample was loaded into the Illumina Beadstudio 2.0 software which converted fluorescent intensities into SNP genotypes.', {'entities': [(77, 85, 'platform')]}),
 ('We initially performed genotyping in a nested case-control study of postmenopausal invasive breast cancer within the NHS cohort () using the Illumina HumanHap550 array, as part of the National Cancer Institute’s Cancer Genetic Markers of Susceptibility (CGEMS) Project ().', {'entities': [(141, 149, 'platform')]}),
 (' We genotyped 318,237 SNPs for each individual, using the Illumina 300 HumanHap SNP Chip.', {'entities': [(58, 66, 'platform')]}),
 (' Genotyping was conducted using the Illumina 550K array.', {'entities': [(36, 44, 'platform')]}),
 (' Genotyping was performed using the Illumina 370 CNV BeadChip system.', {'entities': [(36, 44, 'platform')]}),
 (' Genotyping was done using the Illumina Infinium II assay to query a genome-wide set of 315,176 haplotype-tagging SNP markers (Human HAP300 panel) as well as a focused panel of 45,882 missense and haplotype tagging SNPs.', {'entities': [(31, 39, 'platform')]}),
 ('We carried out high-throughput genome-wide SNP genotyping using Illumina Infinium II HumanHap550 BeadChip technology at the Center for Applied Genomics at CHOP, as previously described.', {'entities': [(64, 72, 'platform')]}),
 (' The samples were genotyped on the Illumina Infinium HumanHap550 version 1 (555352 SNPs) or version 3 (561466 SNPs) BeadChips or the Infinium HD 610-quad BeadChips (598966 SNPs, invariate CNV probes were automatically excluded from the SNP association files).', {'entities': [(35, 43, 'platform')]}),
 (' Only SNPs that were present on each of the three genotyping platforms (Illumina 550v1, 550v3 and 610) were included in the genetic association testing (n  = 535 752).', {'entities': [(72, 80, 'platform')]}),
 ('Genotyping in the CGEMS project was carried out using the Illumina Infinium Sentrix HumanHap550 bead chip, which contains 556 566 SNPs derived from the HapMap phase I and II data ().', {'entities': [(58, 66, 'platform')]}),
 (' There is little risk of strand ambiguities as there are no C/G or A/T polymorphisms included on the Illumina 300K HumanHap panel.', {'entities': [(101, 109, 'platform')]}),
 ('0 (Reich Lab, Harvard University, MA, USA) were included as covariates in age, sex adjusted analyses for CoLaus, GEMs, NFBC, and LOLIPOP Indian Asian Illumina analyses (the number of principal components included varied from 4 to 10, depending on the population structure of the specific cohort).', {'entities': [(150, 158, 'platform')]}),
 ('0 (Reich Lab, Harvard University, MA, USA) were included as covariates in age, sex adjusted analyses for CoLaus, GEMs, NFBC, and LOLIPOP Indian Asian Illumina analyses (the number of principal components included varied from 4 to 10, depending on the population structure of the specific cohort).', {'entities': [(150, 158, 'platform')]}),
 (' Genotyping was conducted using the Illumina 550K array among self-reported Caucasian individuals, and succeeded in 6240 individuals (sample call rate ≥ 97.5%).', {'entities': [(36, 44, 'platform')]}),
 ('We imputed two SNPs, rs16890979 on chromosome 4 and rs1165205 on chromosome 6, which were not on the Illumina Infinium II HumanHap550 SNP chip.', {'entities': [(101, 109, 'platform')]}),
 ('Genome-wide genotyping of the InCHIANTI and BLSA was assessed using the Illumina Infinium HumanHap 550K.', {'entities': [(72, 80, 'platform')]}),
 ('We used the Illumina Human-1 BeadChip.', {'entities': [(12, 20, 'platform')]}),
 ("A total of 90 white TESI cases and 90 gender, race and ethnicity matched controls were genotyped the Illumina Beadstation 500 according to manufacturer's recommended protocol.", {'entities': [(101, 109, 'platform')]}),
 (' In the 274 samples that were genotyped with both the Taqman and Illumina assays, there was 100% agreement at the genotype level.', {'entities': [(65, 73, 'platform')]}),
 (' General population controls were obtained using the Illumina iControlDB client to download genotypes for 3,294 Caucasian individuals with genotype data available from any of the three available HumanHap550k products (v1, v3, and −2v3).', {'entities': [(53, 61, 'platform')]}),
 (' DNA was isolated using the protocol described by DNA Genotek, and SNP genotyping was performed using the Illumina HumanCNV370 BeadChip.', {'entities': [(106, 114, 'platform')]}),
 (' The samples were clustered by first applying Illumina’s cluster definition, removing samples with call rates less than 0.90, and then re-clustering using the samples themselves.', {'entities': [(46, 54, 'platform')]}),
 ('The DNA samples of the CSSCD, BMC, Hong Kong, and Duke subjects were genotyped with the Illumina Human610-Quad SNP array with approximately 600\u2009000 single nucleotide polymorphisms (SNPs) and covers approximately 60% of the genome of the HapMap Yoruban (r_2  > 0.8) and 18\u2009000 known genes.', {'entities': [(88, 96, 'platform')]}),
 (' The MSH DNA samples were genotyped with the Illumina HumanCNV370-duo bead chip or the 317K array.', {'entities': [(45, 53, 'platform')]}),
 ('01 for the gene-based test in the CSSCD dataset based on the following consideration: the average number of SNPs per gene in the Illumina 610 array is 25, so that a P  value less than .', {'entities': [(129, 137, 'platform')]}),
 (' For quality control purposes, any sample that has very low intensity or a very low call rate using the Illumina cluster (<99%) is deleted.', {'entities': [(104, 112, 'platform')]}),
 (' We have used the Illumina 1M and 1M-Duo bead chip data as input into the Penn CNV program [], which allows us to look at deletions (0, 1 copy) as compared to wild type (2 copies) and duplications (3, 4 copies) as compared to wild type (2 copies).', {'entities': [(18, 26, 'platform')]}),
 (' Allele cluster definitions for each SNP were determined using Illumina BeadStudio Genotyping Module version 3.1.', {'entities': [(63, 71, 'platform')]}),
 (' Briefly, samples were genotyped using Infinium II technology from Illumina (HumanHap300 Duo-Plus chip).', {'entities': [(67, 75, 'platform')]}),
 (' Existing data from two sets of controls, genotyped on the Infinium 550k array, were used in stage 1 analyses: the Welcome Trust Case-Control Consortium 1958 birth cohort , and a national colorectal control study using Illumina platform Hap550 array.', {'entities': [(219, 227, 'platform')]}),
 (' For three studies (TOR, NCO, MAY) genotype data were available from an independent, ongoing GWAS study that is also used the Illumina Infinium 610K platform.', {'entities': [(126, 134, 'platform')]}),
 ('0001; (d) all SNPs from the Illumina 1M array on 8q24; (e) all SNPs from the 550k array in the HLA region and (f) all SNPs significant in the CGEMS GWAS with P -trend <.', {'entities': [(28, 36, 'platform')]}),
 ('A total of 1543 ALSPAC children were initially genotyped at 317,504 SNPs on the Illumina HumanHap 317K SNP chip.', {'entities': [(80, 88, 'platform')]}),
 (' The QIMR participants analyzed here were genotyped on the Illumina Human610-Quad SNP chip.', {'entities': [(59, 67, 'platform')]}),
 (' These samples were genotyped in the context of a larger GWAS, which resulted in the genotyping of 16,140 individuals with the use of the Illumina 317, 370, and 610 SNP chips.', {'entities': [(138, 146, 'platform')]}),
 (' The 1,145 women were genotyped using the the Illumina HumanHap500 array as the first stage of a 3 stage GWAS of breast cancer susceptibility.', {'entities': [(46, 54, 'platform')]}),
 (' Additionally, we included 223 cognitively-normal controls with no PD symptoms by self-reported symptom questionnaire () from a previous GWAS () of late-onset Alzheimer disease (LOAD) genotyped using the Illumina HumanHap 550 BeadChip, and another 164 cognitively-normal controls from a second LOAD study with no self-reported PD symptoms by questionnaire () genotyped using the 1M-Duo Infinium HD BeadChip.', {'entities': [(204, 212, 'platform')]}),
 (' Genotypes were determined using Illumina BeadStudio Genotyping Module version 3.2.', {'entities': [(33, 41, 'platform')]}),
 (' Allele cluster definitions for each SNP were determined using Illumina BeadStudio genotyping module version 3.2.', {'entities': [(63, 71, 'platform')]}),
 (' The MSA1 plate was then fragmented with FMS reagent (Illumina) at 37°C for one hour and then precipitated with 2-propanol and incubated at 4°C for 30 minutes.', {'entities': [(54, 62, 'platform')]}),
 (' The resulting blue precipitate was then resuspended in RA1 reagent (Illumina) at 48°C for one hour.', {'entities': [(69, 77, 'platform')]}),
 (' In stage 1, samples from the patients and the Canadian controls were genotyped for 373,400 single-nucleotide polymorphisms (SNPs) with the use of the Illumina HumanHap370 BeadChip.', {'entities': [(151, 159, 'platform')]}),
 (' Anderson historical controls were genotyped on the Illumina HumanHap300 BeadChip.', {'entities': [(52, 60, 'platform')]}),
 ('ADNI participants and approximately two-thirds of the MIRAGE subjects were genotyped on the Illumina Infinium Human 610-Quad BeadChip.', {'entities': [(92, 100, 'platform')]}),
 (' The remaining MIRAGE subjects were genotyped with the Illumina Infinium HUmanCNV370-Duo BeadChip.', {'entities': [(55, 63, 'platform')]}),
 ('All samples were genotyped on the Illumina Human 1M beadchip at the Center for Inherited Disease Research (CIDR) at Johns Hopkins University (Baltimore, MD USA).', {'entities': [(34, 42, 'platform')]}),
 (' Allele cluster definitions for each marker were determined using Illumina BeadStudio Genotyping Module version 3.1.', {'entities': [(66, 74, 'platform')]}),
 (' The Illumina HumanHap550v3 Genotyping BeadChip was used to genotype >550,000 SNPs in these samples.', {'entities': [(5, 13, 'platform')]}),
 (' Of the 14,612 SNPs submitted to Illumina from 764 genes within the anticoagulant, procoagulant, fibrinolytic and innate immunity pathways, 1,585 SNPs (covering 1,100 LD bins) failed manufacture, leaving 13,027 successfully genotyped SNPs.', {'entities': [(33, 41, 'platform')]}),
 ('  The Center for Inherited Disease Research (CIDR), one of two genotyping centers supported by the Gene, Environment Association Studies Consortium (GENEVA) consortium,[] genotyped DNA samples using the Illumina Human660-Quad v.', {'entities': [(203, 211, 'platform')]}),
 (' Genotype clusters for each SNP were determined using the Illumina BeadStudio Module (version 3.3.', {'entities': [(58, 66, 'platform')]}),
 (' Of the 14,612 SNPs submitted to Illumina from 764 genes within the anticoagulant, procoagulant, fibrinolytic and innate immunity pathways, 1,585 SNPs (covering 1,100 LD bins) failed manufacture, leaving 13,027 successfully genotyped SNPs.', {'entities': [(33, 41, 'platform')]}),
 (' The Center for Inherited Disease Research (CIDR), one of two genotyping centers supported by the Gene, Environment Association Studies Consortium (GENEVA) consortium,[] genotyped DNA samples using the Illumina Human660-Quad v.', {'entities': [(202, 210, 'platform')]}),
 (' Genotype clusters for each SNP were determined using the Illumina BeadStudio Module (version 3.3.', {'entities': [(58, 66, 'platform')]}),
 (' Sequencing was performed using Illumina’s HiSeq 2000 sequencer.', {'entities': [(32, 40, 'platform')]}),
 ('GWS (Illumina 660Q; 557,112 SNPs) and CG (n=764 genes relevant to the anticoagulant, procoagulant, fibrinolytic and innate immunity pathways; n=12,551 SNPs) genotypes from the discovery population VTE cases (objectively-diagnosed; no cancer, catheter or antiphospholipid antibodies; n=1503) and controls (frequency-matched on case age, gender, race, MI/stroke status; n= 1459) were merged and imputed to ~2.5 million SNPs (i.', {'entities': [(5, 13, 'platform')]}),
 ('As part of GENEVA, DNA samples were genotyped on the Illumina Human 1M-Duo beadchip by the Center for Inherited Disease Research (CIDR) at Johns Hopkins University.', {'entities': [(53, 61, 'platform')]}),
 (' The Illumina 1M –Duo array has a total of 1,072,820 probes, of which 23,812 are “intensity-only,” leaving 1,049,008 probes as SNP assays.', {'entities': [(5, 13, 'platform')]}),
 (' Genotyping for all cases was performed with the Illumina® Human610–610K Quad platform at the Duke University Center for Human Genome Variation (NC, USA).', {'entities': [(49, 57, 'platform')]}),
 ('DNA samples used in the current study were part of several different projects focused primarily on the genetics of nicotine and alcohol addiction, collected in accordance with standard protocols and were drawn from 5 of 10 Illumina GWAS subsamples (N = 19,257 individuals) genotyped from the Genetic Epidemiology laboratory at QIMR.', {'entities': [(223, 231, 'platform')]}),
 (' DNA samples were genotyped using Illumina HumanCNV370-Quadv3 (N = 966) or Human610-Quadv1 (N = 346) single nucleotide polymorphism (SNP) BeadChips.', {'entities': [(34, 42, 'platform')]}),
 (' Standard QC filters were applied and any SNP was removed unless it satisfied all of the following conditions: mean Illumina Beadstudio GenCall scores ≥ 0.7, SNP call rate > 0.', {'entities': [(116, 124, 'platform')]}),
 (' Genotyping was performed by the Center for Inherited Disease Research using the Illumina Human1M-Duo BeadChip system.', {'entities': [(81, 89, 'platform')]}),
 (' Filtering criteria for genotypic data were: minor allele frequency ≥ 1%, Hardy–Weinberg Equilibrium Test, P  ≥ 10_−6 , SNP call rate > 95% or Illumina Beadstudio GenCall score ≥ 0.7.', {'entities': [(143, 151, 'platform')]}),
 (' Individual genotype data for 1494 participants were extracted from the genomewide array (Illumina 660 Quad Array).', {'entities': [(90, 98, 'platform')]}),
 (' Briefly, the genotyping was performed on the Illumina BeadArray Reader at the Centre for Applied Genomics (Toronto, Ontario, Canada) using 250 nanograms of DNA.', {'entities': [(46, 54, 'platform')]}),
 ('), 43% male) using the Illumina CytoSNP12 array, and imputation of missing HapMap2 genotypes was done using Beagle 3.1.', {'entities': [(23, 31, 'platform')]}),
 ('A total of 555,352 SNP genotype assays were attempted on the 2,494 DNA samples using the Illumina HumanHap550 chip.', {'entities': [(89, 97, 'platform')]}),
 (' Study subjects were genotyped using either the Illumina Infinium Human610-Quad BeadChip or Infinium HumanHap550v3 BeadChip.', {'entities': [(48, 56, 'platform')]}),
 (' The risk SNP BD11934905 () is not on the Illumina 660W array and was not genotyped in this study.', {'entities': [(42, 50, 'platform')]}),
 (' The risk SNP BD11934905 () is not on the Illumina 660W array and was not genotyped in this study.', {'entities': [(42, 50, 'platform')]}),
 (' Considering the relatively low coverage of Illumina HumanHap300 v1.1 BeadChips, we also compared the results by mapping SNPs within 20kb around the gene and by mapping SNPs within 100kb around the gene.', {'entities': [(44, 52, 'platform')]}),
 (' Genotype calls were obtained after scanning on the Illumina BeadStation 500GX and analysis using the GenomeStudio software.', {'entities': [(52, 60, 'platform')]}),
 ('Genotyping in AABC was conducted using the Illumina Human1M-Duo BeadChip.', {'entities': [(43, 51, 'platform')]}),
 (' Genotyping for the TNBCC GWAS was conducted on 1718 cases from 10 studies (ABCTB, BBCC, DFCI, FCCC, GENICA, MARIE, MCBCS, MCCS, POSH, SBCS) using the Illumina 660-Quad SNP array.', {'entities': [(151, 159, 'platform')]}),
 (' In addition, a subset of MARIE cases (n  = 52) was genotyped using the Illumina CNV370 SNP array.', {'entities': [(72, 80, 'platform')]}),
 (' GWAS of breast cancer in Latino (MEC-LAT) and Japanese (MEC-JPT) samples from the MEC were genotyped with the Illumina 660W array at USC.', {'entities': [(111, 119, 'platform')]}),
 (' The concordance for the TaqMan genotyping data with that generated from Illumina for Stage 1 ER-negative cases and controls was 0.997 for rs17530068 and 0.', {'entities': [(73, 81, 'platform')]}),
 (' Genome-wide genotyping was carried out at Decode Genetics (Reykjavik, Iceland) using 3 µg DNA and Illumina Infinium Human Hap300 or CNV370 microarrays, with 310,598 SNPs common to both platforms and hence considered here.', {'entities': [(99, 107, 'platform')]}),
 (' DNA from AAs was genotyped on the Illumina Hum1M Beadarray.', {'entities': [(35, 43, 'platform')]}),
 (' EA DNAs were genotyped on the Illumina Hum550k Beadarray.', {'entities': [(31, 39, 'platform')]}),
 (' To prioritise SNPs for follow-up amongst lower-ranked loci from the Australian GWAS, we performed a fixed-effects meta-analysis of our results (after excluding the 1,230 overlapping samples from Busselton) with those published and made available by the GABRIEL (), which were based on 10,365 asthmatic patients and 16,110 controls genotyped with the Illumina 610K array.', {'entities': [(351, 359, 'platform')]}),
 ('_9 \nDNA samples from subjects who were self‐reported (Northwestern) or observer‐reported (Vanderbilt University) to be African American were genotyped on the Illumina 1M platform.', {'entities': [(158, 166, 'platform')]}),
 ('Genotyping for the discovery set was performed using the Illumina HumanHap300 BeadChip.', {'entities': [(57, 65, 'platform')]}),
 (' Genotyping for the replication set was performed using Illumina BeadXpress 384-plex on the 1,374 subjects.', {'entities': [(56, 64, 'platform')]}),
 (' Flow Chart of the Experimental Process and SNP Selection Criteria    The two GWASs from Hong Kong and Anhui were conducted with the use of the Illumina 610-Quad Human Beadchip array, as previously reported.', {'entities': [(144, 152, 'platform')]}),
 ('  The US NCI GWAS of RCC was based on 1453 RCC cases and 3599 controls of European background from three US and one European study genotyped using Illumina HumanHap HapMap 500, 610 or 660W BeadChips.', {'entities': [(147, 155, 'platform')]}),
 (' The US NCI GWAS of RCC was based on 1453 RCC cases and 3599 controls of European background from three US and one European study genotyped using Illumina HumanHap HapMap 500, 610 or 660W BeadChips.', {'entities': [(146, 154, 'platform')]}),
 (' Genotyping of both cases and controls was performed using Illumina Infinium HumanHap660W arrays ().', {'entities': [(59, 67, 'platform')]}),
 (' Genotyping of cases and controls was performed using either Illumina HumanHap300, 550 or 610 Quad Beadchips ().', {'entities': [(61, 69, 'platform')]}),
 (' For controls we made use of controls from the CGEMS studies of breast and prostate cancers which were genotyped using Illumina HumanHap550 and Phase 1A HumanHap300+Phase 1BHumanHap240 Beadchips respectively (,).', {'entities': [(119, 127, 'platform')]}),
 (' The Icelandic chip-typed samples were assayed with the Illumina Human Hap300, Hap CNV370, Hap 610, 1M or Omni-1 Quad bead chips at deCODE genetics.', {'entities': [(56, 64, 'platform')]}),
 (' The Icelandic chip-typed samples were assayed with the Illumina Human Hap300, Hap CNV370, Hap 610, 1M or Omni-1 Quad bead chips at deCODE genetics.', {'entities': [(56, 64, 'platform')]}),
 (' 1,968 and 35,382 Icelandic case- and control-samples respectively, were successfully assayed with the Infinium HumanHap300 SNP chip (Illumina, SanDiego, CA, USA), containing 317,503 haplotype tagging SNPs derived from phase I of the International HapMap project.', {'entities': [(134, 142, 'platform')]}),
 (' 1,968 and 35,382 Icelandic case- and control-samples respectively, were successfully assayed with the Infinium HumanHap300 SNP chip (Illumina, SanDiego, CA, USA), containing 317,503 haplotype tagging SNPs derived from phase I of the International HapMap project.', {'entities': [(134, 142, 'platform')]}),
 (' In order to assess the association for the SNP rs4962416 on 10q26, which is in the CEU section of the Hapmap database but absent from the Illumina Hap300 chip, we use a method based on haplotypes of two markers (rs7077275 and rs893856) present on the chip.', {'entities': [(139, 147, 'platform')]}),
 (' In order to assess the association for the SNP rs4962416 on 10q26, which is in the CEU section of the Hapmap database but absent from the Illumina Hap300 chip, we use a method based on haplotypes of two markers (rs7077275 and rs893856) present on the chip.', {'entities': [(139, 147, 'platform')]}),
 (' DNA also was genotyped by the Illumina GoldenGate platform for 7 single-nucleotide polymorphisms (SNP; SNP Center, Johns Hopkins University).', {'entities': [(31, 39, 'platform')]}),
 ('5) from the Illumina 1M array, respectively.', {'entities': [(12, 20, 'platform')]}),
 ('  Genotyping was carried out primarily using a Human Omni 1M-duo chip (Illumina), which contains 910,582 SNPs (n  = 1000).', {'entities': [(71, 79, 'platform')]}),
 (' Genotyping was carried out primarily using a Human Omni 1M-duo chip (Illumina), which contains 910,582 SNPs (n  = 1000).', {'entities': [(70, 78, 'platform')]}),
 (' The 116 cases with cardiac neonatal lupus were compared with 3,351 Caucasian controls genotyped on the Illumina HAP300 SNP chip (~317,000 single-nucleotide polymorphisms [SNPs]) from the Consortium on Systemic Lupus Erythematosus (SLE) Genetics ().', {'entities': [(104, 112, 'platform')]}),
 ('Genomic DNA samples (750 ng) isolated from RRNL cases (described above) were genotyped on the Illumina BeadStation 500GX following standard manufacturing protocols.', {'entities': [(94, 102, 'platform')]}),
 ('A set of 374 SNPs on the Illumina 317K SNP chip that had previously been implicated as being associated with autoimmune diseases were identified from published genome-wide association studies; 207 of these passed our statistical quality control standards.', {'entities': [(25, 33, 'platform')]}),
 (' Individuals were genotyped on the Illumina HumanHap500 version 3 BeadChip.', {'entities': [(35, 43, 'platform')]}),
 (' The subjects were genotyped on the Illumina 1M version 1 BeadChip.', {'entities': [(36, 44, 'platform')]}),
 (' In the two Canadian cohorts, rs321588, rs7751374, rs10124954, and rs6499255 were genotyped on the Illumina Human610-Quad array; rs9469220, rs537526, and rs16977747 were imputed using MACH; rs2885872 was a genotyped proxy (CEU r_2 =1.0) used for rs2363709; and rs10043454 and rs4355582 were imputed proxies used for rs13361473 and rs10944017, respectively.', {'entities': [(99, 107, 'platform')]}),
 ('Genotyping for the 574 phase 1 breast cancer cases was conducted using the Illumina 660-Quad SNP array.', {'entities': [(75, 83, 'platform')]}),
 (' Genotyping for the replication samples from Helsinki was conducted using the Illumina 550 platform as previously described ().', {'entities': [(78, 86, 'platform')]}),
 (' The intensity data generated was loaded into Illumina’s Genome studio and genotypes were generated using a GenCall threshold of 0.15.', {'entities': [(46, 54, 'platform')]}),
 (' DILGOM and GenMets were genotyped with the Illumina HumanHap 610k array.', {'entities': [(44, 52, 'platform')]}),
 (' Biotinylated cDNA (750 ng) was hybridized to Illumina HumanHT-12 Expression BeadChips according to the manufacturer’s protocol.', {'entities': [(46, 54, 'platform')]}),
 (' The genotyping was performed using Illumina HumanHap 670k custom arrays, and genotypes were clustered using the Illuminus algorithm.', {'entities': [(36, 44, 'platform')]}),
 (' Allele cluster definitions for each SNP were determined using Illumina BeadStudio Genotyping Module (Version 2.3.', {'entities': [(63, 71, 'platform')]}),
 (' For the African Caribbean Version 3 sample set, allele cluster definitions were determined using the combined intensity data from 96 study samples and HapMap controls genotyped together, plus 120 HapMap samples genotyped at Illumina using BeadStudio Genotyping Module (Version 3.1.', {'entities': [(225, 233, 'platform')]}),
 ('Genotyping for the AGS discovery subjects was conducted by deCODE Genetics using Illumina’s HumanCNV370-duo BeadChip as previously described ().', {'entities': [(81, 89, 'platform')]}),
 (' Genotyping for the Mayo Clinic study subjects was performed using Illumina 610Quad SNP arrays as previously described ().', {'entities': [(67, 75, 'platform')]}),
 (' () Genotyping for the TCGA study subjects was performed using Illumina 550 platform.', {'entities': [(63, 71, 'platform')]}),
 ('DNA samples were genotyped using the Illumina HumanOmniExpress BeadChip, consisting of 729 755 SNPs, at the Center for Cancer Genomics, Wake Forest University.', {'entities': [(37, 45, 'platform')]}),
 ('Genotypes for DNA samples extracted from blood were determined at the RIKEN Center for Genomic Medicine in Yokahama, Japan, with Illumina Human610-Quad BeadChips.', {'entities': [(129, 137, 'platform')]}),
 (', San Diego, CA)[], except for the MAGICS/ISAAC data set (Illumina HumanHap300 BeadChip, thus contributing with 300K SNPs in the analysis).', {'entities': [(58, 66, 'platform')]}),
 ('Genotyping was conducted using an Illumina HumanOmniExpress BeadChip system (729,755; single nucleotide polymorphisms [SNPs] included) at the Center for Cancer Genomics, Wake Forest University School of Medicine.', {'entities': [(34, 42, 'platform')]}),
 ('All 484 subjects with multiple sclerosis were typed for 553 139 SNPs using the Illumina 550k platform with < 2% of genotyping failure rate per sample ().', {'entities': [(79, 87, 'platform')]}),
 ('The Center for Inherited Disease Research (CIDR) genotyped samples using the Illumina Human610-Quad v.', {'entities': [(77, 85, 'platform')]}),
 (' Cells were collected at days 3, 5, 7, 9 and 10 in three biological replicates and gene expression was assayed using Illumina human WGv3.0 microarrays.', {'entities': [(117, 125, 'platform')]}),
 (' CGEMS is based on 1,145 cases and 1,142 controls drawn from the Nurses Health Study (see URLs) which were genotyped using the Illumina 550k array.', {'entities': [(127, 135, 'platform')]}),
 (' Genotyping was performed at The Rockefeller University Genomics Resource Center using the Illumina 300K SNP Infinium platform (Sentrix HumanHap 300) according to the manufacturer’s recommended protocol.', {'entities': [(91, 99, 'platform')]}),
 (' We also assessed the frequency of these rare CNVs in a set of population-based controls, which were genotyped for another study using the Illumina 370K SNP array.', {'entities': [(139, 147, 'platform')]}),
 (' Samples were genotyped on the Illumina HumanHap550 (~550,000 SNPs) or 610Q platforms (~610,000 SNPs).', {'entities': [(31, 39, 'platform')]}),
 (' The Illumina 610Q contains the great majority of the HumanHap 550 set of SNP markers plus additional copy number variants.', {'entities': [(5, 13, 'platform')]}),
 (' We identified a set of SNP markers common to both the Illumina 610Q platform and the HumanHap 550 platform as our genotype set.', {'entities': [(55, 63, 'platform')]}),
 (' All subjects were genotyped on the Illumina Human 1M beadchip.', {'entities': [(36, 44, 'platform')]}),
 (' Genome-wide genotyping was performed using Illumina Human Hap550K chip.', {'entities': [(44, 52, 'platform')]}),
 (' The controls had been genotyped using Illumina HumanHap550 Bead Chips.', {'entities': [(39, 47, 'platform')]}),
 (' The Illumina Human610-Quad Beadchip was used to obtain genotypes for all cases, resulting in 599 011 successfully genotyped SNPs.', {'entities': [(5, 13, 'platform')]}),
 (' The Illumina HumanHap550 (v.', {'entities': [(5, 13, 'platform')]}),
 ('1) SNP Beadchip was used to obtain genotypes for the CGEMS breast cancer controls, and the Illumina HumanHap250S (v1.0) and HumanHap300 (v1.', {'entities': [(91, 99, 'platform')]}),
 ('981) failed Illumina scoring and were replaced with a highly correlated tag SNP (rs9268544, r_2  = 1.0 for both SNPs).', {'entities': [(12, 20, 'platform')]}),
 (' The Illumina Human610-Quad Beadchip was used to obtain genotypes for all cases, resulting in 599 011 successfully genotyped SNPs.', {'entities': [(5, 13, 'platform')]}),
 (' The Illumina HumanHap550 (v.', {'entities': [(5, 13, 'platform')]}),
 ('1) SNP Beadchip was used to obtain genotypes for the CGEMS breast cancer controls, and the Illumina HumanHap250S (v1.0) and HumanHap300 (v1.', {'entities': [(91, 99, 'platform')]}),
 ('981) failed Illumina scoring and were replaced with a highly correlated tag SNP (rs9268544, r_2  = 1.0 for both SNPs).', {'entities': [(12, 20, 'platform')]}),
 (' In total, 1,191 cases and 999 controls were successfully genotyped on the Illumina 1M/1M Duo platform and passed all quality-control (QC) steps.', {'entities': [(75, 83, 'platform')]}),
 ('  Genotyping was completed on the Illumina Human1M and Human1M-Duo Bead Array in accordance with the manufacturer’s protocol.', {'entities': [(34, 42, 'platform')]}),
 ('  Genotyping was completed using Illumina HumanHap300 and HumanHap240S (PLCO), 550k (WHI, DALS) and 610k (DALS, PLCO) BeadChip Array System on the Infinium platform in accordance with the manufacturer’s protocol or as previously described for HumanHap300 and HumanHap240S ().', {'entities': [(33, 41, 'platform')]}),
 (' This included SNPs reported by Illumina as not performing consistently across platforms (n=78), SNPs found to have more than one discordant call across the 550K and 610K platforms in HapMap Data or our interplatform duplicates (n=185); and SNPs with different MAF calls on the two platforms in our control populations (n=9).', {'entities': [(32, 40, 'platform')]}),
 (' For CCFR phase II, samples were genotyped using the Illumina 1M Omni.', {'entities': [(53, 61, 'platform')]}),
 (' Genotyping was completed on the Illumina Human1M and Human1M-Duo Bead Array in accordance with the manufacturer’s protocol.', {'entities': [(33, 41, 'platform')]}),
 (' Genotyping was completed using Illumina HumanHap300 and HumanHap240S (PLCO), 550k (WHI, DALS) and 610k (DALS, PLCO) BeadChip Array System on the Infinium platform in accordance with the manufacturer’s protocol or as previously described for HumanHap300 and HumanHap240S ().', {'entities': [(32, 40, 'platform')]}),
 (' This included SNPs reported by Illumina as not performing consistently across platforms (n=78), SNPs found to have more than one discordant call across the 550K and 610K platforms in HapMap Data or our interplatform duplicates (n=185); and SNPs with different MAF calls on the two platforms in our control populations (n=9).', {'entities': [(32, 40, 'platform')]}),
 (' This included SNPs reported by Illumina as not performing consistently across platforms (n=78), SNPs found to have more than one discordant call across the 550K and 610K platforms in HapMap Data or our interplatform duplicates (n=185); and SNPs with different MAF calls on the two platforms in our control populations (n=9).', {'entities': [(32, 40, 'platform')]}),
 (' For CCFR phase II, samples were genotyped using the Illumina 1M Omni.', {'entities': [(53, 61, 'platform')]}),
 ('Genomic DNA from 1,440 AD cases was genotyped using the Illumina HumanOmni1-Quad as part of the stage 1 discovery sample.', {'entities': [(56, 64, 'platform')]}),
 ('2 % women) which were previously genotyped using the Illumina HumanHap300 BeadChip.', {'entities': [(53, 61, 'platform')]}),
 ('AD GWAS dataset consists of 188 AD cases with a clinical diagnosis of AD at baseline visit that were genotyped using the Illumina 610- Quad BeadChip.', {'entities': [(121, 129, 'platform')]}),
 ('The University of Pittsburgh ADRC sample of 1,440 AD cases was genotyped using the Illumina Omni1-Quad chip (containing probes for 1,016,423 SNPs and/or copy-number variations) at the Feinstein Institute of Medical Research (Manhasset, NY).', {'entities': [(83, 91, 'platform')]}),
 (' To check comparability between the 2 Caribbean Hispanic data sets and to check SNP calling between the Illumina 650Y and 610K SNP chips, we compared allele frequencies for common randomly selected SNPs.', {'entities': [(104, 112, 'platform')]}),
 (' All AD cases and 955 controls were genotyped at the Sanger Institute on the Illumina 610-quad chip.', {'entities': [(77, 85, 'platform')]}),
 (' Genotyping for Pittsburgh subjects was performed using the Illumina Omni1-Quad chip (containing probes for 1.13 million SNPs).', {'entities': [(60, 68, 'platform')]}),
 (' Using the software Tagger as implemented in Haploview (,) and data from the CEPH population in the International HapMap project, release 2 (,), we designed a panel of 4905 SNPs that were compatible with the Illumina Infinium technology, of which 4650 SNPs remained for analysis following clustering quality control.', {'entities': [(208, 216, 'platform')]}),
 (' Using the software Tagger as implemented in Haploview (,) and data from the CEPH population in the International HapMap project, release 2 (,), we designed a panel of 4905 SNPs that were compatible with the Illumina Infinium technology, of which 4650 SNPs remained for analysis following clustering quality control.', {'entities': [(208, 216, 'platform')]}),
 ('  The primary scan for the discovery population of RCC case–control study (910 cases and 566 controls) was performed at MD Anderson Cancer Center using the Illumina HumanHap660W Beadchips.', {'entities': [(156, 164, 'platform')]}),
 (' The primary scan for the discovery population of RCC case–control study (910 cases and 566 controls) was performed at MD Anderson Cancer Center using the Illumina HumanHap660W Beadchips.', {'entities': [(155, 163, 'platform')]}),
 (' Genome-wide SNP typing was performed using Illumina 317K, 370K or 610K chips at CIDR, deCode Genetics or the Finnish Genome Centre.', {'entities': [(44, 52, 'platform')]}),
 (' Individual genotype data were extracted from the genome-wide Illumina 660 Quad Array.', {'entities': [(62, 70, 'platform')]}),
 (' In this discovery phase, we adopted a joint analysis strategy; that is, 806 cases and 1337 controls were genotyped with the Infinium HumanHap550 or Human610-Quad BeadArray (Illumina, San Diego, CA, USA) in stage 1a, and only the top hit SNPs were followed up for fast track  in stage 1b ().', {'entities': [(174, 182, 'platform')]}),
 ('The Illumina Sentrix HumanHap550v3 genotyping BeadChips were used.', {'entities': [(4, 12, 'platform')]}),
 (' GWAS of the JHH case population was performed using the Illumina 610K chip ().', {'entities': [(57, 65, 'platform')]}),
 (' GWAS of the iControls population () was performed using Illumina Hap300 and Hap550 chips.', {'entities': [(57, 65, 'platform')]}),
 (' Genome-wide SNP genotyping for CAMP subjects was performed on either Illumina’s HumanHap550 or Human610-Quad BeadChip and imputation was performed using MACH based on 1000 Genomes Project haplotypes.', {'entities': [(70, 78, 'platform')]}),
 (' Genome-wide SNP genotyping for CAMP subjects was performed on either Illumina’s HumanHap550 or Human610-Quad BeadChip and imputation was performed using MACH based on 1000 Genomes Project haplotypes.', {'entities': [(70, 78, 'platform')]}),
 (' The CGEMS project included 1,145 post-menopausal breast cancer cases from the NHS whose DNA samples were scanned using the Illumina HumanHap500 array (, ).', {'entities': [(124, 132, 'platform')]}),
 (' All cohorts were of self-described European white ancestry and genotyped on Illumina platforms (Human Hap550 or Quad610).', {'entities': [(77, 85, 'platform')]}),
 (' Samples from self-described European whites were genotyped at the Center for Inherited Disease Research (CIDR) at Johns Hopkins University using the Illumina Omni1 Quad platform.', {'entities': [(150, 158, 'platform')]}),
 ('05, Illumina GC scores of >0.8 and present in HapMap CEU subjects.', {'entities': [(4, 12, 'platform')]}),
 (' DNA samples for the first-stage GWAS were genotyped with use of the Illumina HumanOmni1-Quad_v1-0_B array and were called using the BeadStudio algorithm, at the John Hopkins University Center for Inherited Disease Research (CIDR).', {'entities': [(69, 77, 'platform')]}),
 (' In addition, we genotyped the rest of the CM cases identified in both cohorts who were not in these previous GWASs by Illumina 610. Finally, we included 494 CM cases and 5628 controls.', {'entities': [(119, 127, 'platform')]}),
 ('  DNA was genotyped with the Illumina Human610-Quad BeadChip, and 514,073 SNPs passed quality control filters (SNP call rate > 95%, minor allele frequency > 5%, Hardy–Weinberg disequilibrium P  < 1 × 10_−6 ) and were merged with 34 European reference populations.', {'entities': [(29, 37, 'platform')]}),
 (' DNA was genotyped with the Illumina Human610-Quad BeadChip, and 514,073 SNPs passed quality control filters (SNP call rate > 95%, minor allele frequency > 5%, Hardy–Weinberg disequilibrium P  < 1 × 10_−6 ) and were merged with 34 European reference populations.', {'entities': [(28, 36, 'platform')]}),
 ('  DNA was genotyped with the Illumina Human660W-Quad BeadChip, and 494,082 SNPs passed quality control filters (sample call rate > 98%, SNP call rate > 95%, minor allele frequency > 5%, Hardy–Weinberg disequilibrium P  < 1 × 10_−6 ) and were merged with Hapmap European reference populations; 599 individuals were removed as genetic outliers based on PCA of an allele-sharing distance matrix.', {'entities': [(29, 37, 'platform')]}),
 (' DNA was genotyped with the Illumina Human660W-Quad BeadChip, and 494,082 SNPs passed quality control filters (sample call rate > 98%, SNP call rate > 95%, minor allele frequency > 5%, Hardy–Weinberg disequilibrium P  < 1 × 10_−6 ) and were merged with Hapmap European reference populations; 599 individuals were removed as genetic outliers based on PCA of an allele-sharing distance matrix.', {'entities': [(28, 36, 'platform')]}),
 ('21 × 10_−5  as proposed for the Illumina 317K panel of markers (adjusted for SNP non-independence) ().', {'entities': [(32, 40, 'platform')]}),
 ('All genome-wide SNP genotyping for the discovery cohorts was performed using the Illumina HumanHap550 BeadChip at the Center for Applied Genomics at the Children’s Hospital of Philadelphia.', {'entities': [(81, 89, 'platform')]}),
 (' The first replication case series was genotyped by Illumina Human610 BeadChip, yet two additional replication case series were genotyped by TaqMan.', {'entities': [(52, 60, 'platform')]}),
 (' Samples were genotyped using the Illumina 550K and 610-Quad platforms (, ).', {'entities': [(34, 42, 'platform')]}),
 (' Samples were genotyped using the Illumina 550K and 610-Quad platforms (, ).', {'entities': [(34, 42, 'platform')]}),
 (' Forty-seven samples were initially genotyped on the Illumina Infinium 610-Quad, followed by an additional 40 samples (including 8 duplicates) on the 660-Quad.', {'entities': [(53, 61, 'platform')]}),
 (' Genotyping for discovery cohorts was centrally performed on the Illumina Human 610quad BeadChip at the Centre National de Génotypage (CNG, Evry, France).', {'entities': [(65, 73, 'platform')]}),
 ('A custom Illumina genotyping array was designed with 768 SNPs that included: Known causative mutations:  SNPs that genotyped two common LRRK2  mutations in European populations (G2019S and R1441H); Known risk factors: GBA  (N370S, L444P, E326K, T369M); Previous GWAS associations: PARK16 , LRRK2 _, , SNCA , MAPT _– , GAK _, , the HLA region; Sex confirmation:  3 SNPs on the Y chromosome and 6 SNPs on the X chromosome in addition to the sex-specific probes included in the GoldenGate custom oligonucleotide pool; Top priority association results from the meta-analysis:  SNPs were selected based on increasing p-value.', {'entities': [(9, 17, 'platform')]}),
 ('80) with a SNP having a smaller p-value or had an Illumina design score less than 0.40 (if p<1 × 10_−5 ) or 0.', {'entities': [(50, 58, 'platform')]}),
 ('05) with any marker with a larger F_ST , or if it had an Illumina design score less than 0.80.', {'entities': [(57, 65, 'platform')]}),
 (' Samples were genotyped by the Genetic Resource Core Facility SNP Center at Johns Hopkins University using Illumina GoldenGate chemistry and a custom panel of 768 SNPs (GS0012520-OPA) (see ).', {'entities': [(107, 115, 'platform')]}),
 (' Baseline characteristics of studies included in the GWAS meta-analysis of OA-phenotypes GWA = genome-wide association; OA = osteoarthritis; NA = not applicable/availableGWAS Rotterdam Study (discovery study): genotyping of the samples with the Illumina HumanHap550v3 Genotyping BeadChip was carried out at the Genetic Laboratory of the Department of Internal Medicine of Erasmus Medical Center, Rotterdam, the Netherlands.', {'entities': [(245, 253, 'platform')]}),
 (' GWAS Rotterdam Study (discovery study):deCODE: all samples were assayed with the Infinium HumanHap 300 or humanCNV370 SNP chips (Illumina), containing 317,503 tagging SNPs derived from phase I of the International HapMap project.', {'entities': [(130, 138, 'platform')]}),
 ('Genome-wide SNP genotyping was performed in the CAMP sample by Illumina, Inc, on the HumanHap550v3 BeadChip.', {'entities': [(63, 71, 'platform')]}),
 (' SNPs were removed for the following reasons: (1) 6,257 markers were removed because of low Illumina clustering scores; (2) 1,379 markers were removed because their flanking sequences did not map to a unique position on the hg17  reference genome sequence; (3) 3,790 markers were removed because they were monomorphic in our sample; and (4) 2,445 markers were removed because of 5 or more parent-child genotype inconsistencies.', {'entities': [(92, 100, 'platform')]}),
 (' SNPs were genotyped with an Illumina BeadStation 500G and with a Sequenom MassArray matrix-assisted laser desorption/ionization time-of-flight mass spectrometer (Sequenom, Inc, San Diego, Calif).', {'entities': [(29, 37, 'platform')]}),
 (' Genotyping of the samples in the discovery cohorts (RS-I and RS-II) was carried out with the Illumina HumanHap 550v3 Genotyping BeadChip.', {'entities': [(94, 102, 'platform')]}),
 (' The HumanHT-12 Expression BeadChips (Illumina Inc, San Diego, CA, USA) contains 48,803 probes that cover more than 25,000 annotated genes.', {'entities': [(38, 46, 'platform')]}),
 (' Expression data were collated and quality checked in the Illumina BeadStudio and then imported into GeneSpring V10.0 (Agilent Technologies, Santa Clara, CA, USA).', {'entities': [(58, 66, 'platform')]}),
 (' Data were quantile normalized to the baseline of the median of all samples and then filtered using an Illumina detection score of 0.95 or greater in at least one sample.', {'entities': [(103, 111, 'platform')]}),
 (' Mayo VTE genotyping was performed as part of a larger GWAS of VTE using the Illumina 660W Quad array at the Center for Inherited Disease Research at Johns Hopkins University.', {'entities': [(77, 85, 'platform')]}),
 (' Mayo PGRN subjects who provided blood samples as a source of DNA (n  = 835) were genotyped using the Illumina 610K array, performed at RIKEN, with 830 cases passing genotype quality control.', {'entities': [(102, 110, 'platform')]}),
 (' The Mayo PGRN study contributed data only for those 104 SNPs which were directly genotyped on the Illumina 610K platform.', {'entities': [(99, 107, 'platform')]}),
 ('Of the 726 European-Americans included in the GWAS analysis, 671 (due to sample availability) were also genotyped on the Immunochip, a custom Illumina Infinium array (196,524 SNPs) designed for replication and fine mapping of established GWAS loci and strong candidate genes for autoimmune and inflammatory diseases [].', {'entities': [(142, 150, 'platform')]}),
 (' Stage 1 included data on 1894 controls and 1854 cases genotyped for 541,129 SNPs using an Illumina Infinium 550k array.', {'entities': [(91, 99, 'platform')]}),
 (' CGEMS included 2277 samples (1101 controls and 1176 cases) genotyped for 546,613 SNPs using the Illumina 317K and 240K arrays.', {'entities': [(97, 105, 'platform')]}),
 (' Stage 1 included data on 1894 controls and 1854 cases genotyped for 541,129 SNPs using an Illumina Infinium 550k array.', {'entities': [(91, 99, 'platform')]}),
 (' CGEMS included 2277 samples (1101 controls and 1176 cases) genotyped for 546,613 SNPs using the Illumina 317K and 240K arrays.', {'entities': [(97, 105, 'platform')]}),
 (' The DNA samples were collected in accordance with standard protocols and were genotyped using the following Illumina SNP platforms: 317K, HumanCNV370-Quadv3, and Human610-Quad.', {'entities': [(109, 117, 'platform')]}),
 (' NIDDK controls consisted of 895 individuals of non-Jewish, European ancestry that were genotyped with the Illumina HumanHap300 Beadchip and were without history of inflammatory bowel disease.', {'entities': [(107, 115, 'platform')]}),
 (' The NINDS controls consisted of 943 Caucasian, non-Hispanic individuals that were genotyped with the Illumina HumanCNV370 Beadchip and were negative for neurological disease by self-report.', {'entities': [(102, 110, 'platform')]}),
 (' The data retrieved from IntraGen Population Genetics Database (IntraGenDB) consisted of 478 individuals between the ages of 30 and 60, of non-Jewish white ancestry, genotyped with the Illumina HumanHap300 genotyping platform.', {'entities': [(185, 193, 'platform')]}),
 (' For this purpose, we included autosomal SNPs present on the Illumina Human 370-quad chip and in HapMap release 23a for which we downloaded genotype data for 210 unrelated HapMap samples (60 CEU, 45 HCB, 45 JPT and 60 YRI) (www.', {'entities': [(61, 69, 'platform')]}),
 (' For this purpose, we included autosomal SNPs present on the Illumina Human 370-quad chip and in HapMap release 23a for which we downloaded genotype data for 210 unrelated HapMap samples (60 CEU, 45 HCB, 45 JPT and 60 YRI) (www.', {'entities': [(61, 69, 'platform')]}),
 (' We selected autosomal SNPs >100 kb apart and present on the Illumina CNV370 beadchip (a full list of SNPs is available upon request).', {'entities': [(61, 69, 'platform')]}),
 (' For SCORM, a total of 1116 DNA samples (1037 from buccal swab and 79 from saliva) were genotyped using Illumina HumanHap 550 or 550 Duo Beadarrays®.', {'entities': [(104, 112, 'platform')]}),
 (' For SP2, a total of 2867 blood-derived samples were genotyped using Illumina HumanHap 550v3, 610Quad, and 1Mduov3 platforms.', {'entities': [(69, 77, 'platform')]}),
 (' For SCORM, a total of 1116 DNA samples (1037 from buccal swab and 79 from saliva) were genotyped using Illumina HumanHap 550 or 550 Duo Beadarrays®.', {'entities': [(104, 112, 'platform')]}),
 (' For SP2, a total of 2867 blood-derived samples were genotyped using Illumina HumanHap 550v3, 610Quad, and 1Mduov3 platforms.', {'entities': [(69, 77, 'platform')]}),
 ('Since the genotype data were not generated from a single Illumina Beadarray platform (two for SCORM and three for SP2), we analyzed all common markers in the dataset(s) tested.', {'entities': [(57, 65, 'platform')]}),
 ('Genotype data were obtained with Illumina 317K, 370K or 610K arrays and stringent quality control (QC) procedures applied to ensure high data quality as described in detail previously and summarised in Supplementary Table 2. After QC, genotype data were available for 16\u2009140 individuals and 561\u2009815 SNPs.', {'entities': [(33, 41, 'platform')]}),
 ('1 based on the SNP and CNV probes present in the Illumina 610K arrays.', {'entities': [(49, 57, 'platform')]}),
 (' These individuals were ascertained from the same QIMR studies that contributed data to the GWAS (Supplementary Table 2) and were recently typed with Illumina 610K arrays as part of an additional, as yet unpublished wave of genotyping conducted in the first semester of 2010. All samples are of European descent and passed the standard QC filters described above for the GWAS.', {'entities': [(150, 158, 'platform')]}),
 ('Significant SNPs from the joint CKGen and CARe meta-analysis were replicated in the DCCT/EDIC Study, which currently consists of 1304 Caucasian participants who underwent genotyping on the Illumina 1M SNP chip.', {'entities': [(189, 197, 'platform')]}),
 ('Genotyping for the lung study controls was completed using Illumina’s HumanHap300 v1.1 BeadChips with 317K tagging SNPs ().', {'entities': [(59, 67, 'platform')]}),
 (' Genotyping analyses for the bladder cancer () and renal cancer studies were performed using Illumina’s HumanHap610 chip and HumanHap660 chip, respectively.', {'entities': [(93, 101, 'platform')]}),
 ('We used the Illumina Infinium 370 CNV chip to obtain GWA data on the cases (See , Genome-wide association screen: subjects and selection of SNPs).', {'entities': [(12, 20, 'platform')]}),
 (" Genotyping methods included an Illumina Goldengate custom panel and, for failed or undesignable SNPs, the Taqman 5' nuclease discrimination assay.", {'entities': [(32, 40, 'platform')]}),
 ('SGENE was initially made up of 1,321 cases and 12,277 controls typed at deCODE Genetics using the Illumina HumanHap300 BeadChip.', {'entities': [(98, 106, 'platform')]}),
 (' Out of the 5110 coffee drinkers, 2680 have been genotyped on a chip containing the Illumina 317K set of SNPs in one of several genome-wide association studies conducted by deCODE Genetics.', {'entities': [(84, 92, 'platform')]}),
 (' The US samples were genotyped on the Illumina Human1M chip.', {'entities': [(38, 46, 'platform')]}),
 (' Additionally, all markers were re-genotyped on >10% of samples typed with the Illumina platform resulting in an observed mismatch in <0.5% of samples.', {'entities': [(79, 87, 'platform')]}),
 ('The TwinsUk sample has been genotyped using the Illumina HumanHap 300k duo chip, and population substructure has been detected and removed as described previously [].', {'entities': [(48, 56, 'platform')]}),
 (' For the Leeds sample, genotyping data from the Illumina HumanHap300 v2 array were available for the 123 familial cases and for 148 cases and 167 controls (Leeds1 sample).', {'entities': [(48, 56, 'platform')]}),
 (' Both Leeds1 and Leeds2 case-control sample were supplemented with genotyping information from the Wellcome Trust Case-Control Consortium (WTCCC) 1958 birth cohort control samples analysed on the Illumina 550k array.', {'entities': [(196, 204, 'platform')]}),
 (' Both rapid progressors (AIDS, by the CDC 1993 definition, within 3 years of seroconversion) and slow progressors (CD4+ cell count >500 cells/mL and no clinical symptoms of AIDS at least 8 years after seroconversion) from the French GRIV cohort were typed using the Illumina HumanHap300 genotyping beadchips [, ], as were rapid progressors and controls in the Amsterdam Cohort Study (ACS.', {'entities': [(266, 274, 'platform')]}),
 (" Genotype data from 640 previously QC'd controls, all free of inflammatory diseases, was combined with common controls from the same Epidemiological Investigation of Rheumatoid Arthritis genotyped on the Illumina Hap550 (N=460) and Quad-610 (N=378) BeadChips (total of 1,478 controls).", {'entities': [(204, 212, 'platform')]}),
 ('As all studies utilized compatible Illumina platforms, we combined 266,047 (258,137 autosomal and 7,910 X chromosome) SNPs passing QC in all three studies.', {'entities': [(35, 43, 'platform')]}),
 (' DNA samples were genotyped with the Illumina Human1M (n individuals=1,973; m=1,072,820 SNPs) or Human1M-Duo (n individuals=374; m=1,199,187 SNPs) BeadChip platforms.', {'entities': [(37, 45, 'platform')]}),
 (' The Human1M and Human1M-Duo contain 415 and 436 SNPs, respectively, that were genotyped as part of a candidate gene study on the Illumina GoldenGate platform on a subset of the individuals genotyped in this study (N=444).', {'entities': [(130, 138, 'platform')]}),
 (' All SNPs with borderline significant associations underwent additional quality control checks including:\n\n visual inspection of genotype clusters; verification of genotype concordance between HapMap samples genotyped by Illumina on the Human1M and Human1M-Duo and with HapMap phase II release 24; verification of no major MAF difference in controls genotyped on the Human1M and Human1M-Duo.', {'entities': [(221, 229, 'platform')]}),
 (' The selected SNPs were extracted from a larger set of SNPs genotyped in 2,433 unique samples on a custom 10,640-bead iSelect array from Illumina designed for 7703 SNPs.', {'entities': [(137, 145, 'platform')]}),
 (' 8q24-rs1050477 and 9p24-rs719725 (, ) were not available on the Illumina Human1M or Human1M-Duo.', {'entities': [(65, 73, 'platform')]}),
 ('Genotypes were generated using Illumina’s HumanHap300 BeadChip (San Diego, CA) for the 1154 patients included in our previous genome-wide association studies of lung cancer risk ().', {'entities': [(31, 39, 'platform')]}),
 (' We carried out genotyping for an additional 81 patients from MD Anderson Cancer Center using Illumina’s HumanHap317 BeadChip.', {'entities': [(94, 102, 'platform')]}),
 (' In EDIC, the Illumina platform was used for which 550K SNPs were available.', {'entities': [(14, 22, 'platform')]}),
 (' In the EDIC cohort, subjects were genotyped on the Illumina HumanHap550 composed of ∼550 000 SNPs.', {'entities': [(52, 60, 'platform')]}),
 (" We performed genotyping in BC_NHS using the Illumina HumanHap550 array, as part of the National Cancer Institute's Cancer Genetic Markers of Susceptibility (CGEMS) Project ().", {'entities': [(45, 53, 'platform')]}),
 (' (i) The genotyping for the KS_NHS_HPFS was performed using the Illumina HumanHap610 Quad, and the imputation was performed in the same fashion as in the discovery set.', {'entities': [(64, 72, 'platform')]}),
 (" We performed genotyping in BC_NHS using the Illumina HumanHap550 array, as part of the National Cancer Institute's Cancer Genetic Markers of Susceptibility (CGEMS) Project ().", {'entities': [(45, 53, 'platform')]}),
 (' (i) The genotyping for the KS_NHS_HPFS was performed using the Illumina HumanHap610 Quad, and the imputation was performed in the same fashion as in the discovery set.', {'entities': [(64, 72, 'platform')]}),
 (' On the Illumina Human-1 Genotyping BeadChip about 109,000 exon-centric SNPs can be interrogated.', {'entities': [(8, 16, 'platform')]}),
 (' The Illumina HumanHap300 Genotyping BeadChip comprises about 317,000 SNPs.', {'entities': [(5, 13, 'platform')]}),
 (' We obtained a genotype concordance rate with the genotypes produced by the Illumina assays of >99.9%.', {'entities': [(76, 84, 'platform')]}),
 (' studies, all subjects had been genotyped on the Illumina 610k-Quad Beadchips.', {'entities': [(49, 57, 'platform')]}),
 (' Extracted RNA was quality checked on the Agilent 2100 Bioanalyser, subjected to two rounds of linear amplification and hybridised to Illumina MouseRef-8 v1.0 Expression BeadChips according to the manufacturer’s protocol (see also ).', {'entities': [(134, 142, 'platform')]}),
 ('Genomewide analysis of samples that were initially available from the 22 Liverpool subjects with carbamazepine-induced hypersensitivity syndrome was performed with the use of the Illumina Infinium 1.2M chip at the Wellcome Trust Sanger Institute.', {'entities': [(179, 187, 'platform')]}),
 (' Samples from 43 case subjects and 200 control subjects from the EPIGEN consortium were genotyped with the use of the Illumina 610K Quad platform at the Duke University Center for Human Genome Variation.', {'entities': [(118, 126, 'platform')]}),
 (' All subjects were genotyped using the Illumina Human1M-Duo BeadChip, containing 1,072,820 markers.', {'entities': [(39, 47, 'platform')]}),
 (' All subjects were genotyped using the Illumina Human1M-Duo BeadChip, containing 1,072,820 markers.', {'entities': [(39, 47, 'platform')]}),
 ('0, GeneChip 500K, 250K, MIP50K and 10K) and Illumina (HumanHap 550K, 318K, HumanHap 300K, HumanHap 370K CNV, HumanHap610 quad, Human660W-Quad BeadChip, 6K and Human 1Mv1_C) genotyping arrays.', {'entities': [(44, 52, 'platform')]}),
 (' BeadChips were imaged on the Illumina BeadStation 500 GX at the Center for Human Genomics at Wake Forest University.', {'entities': [(30, 38, 'platform')]}),
 (' Plots and corresponding inflation values are shown for both normalization methodsThirty-six SNPs from the Illumina HuHap550 array were genotyped individually using the Sequenom MassArray Genotyping platform (Sequenom Inc, San Diego, CA) on all case and control samples used in the pooling GWAS.', {'entities': [(107, 115, 'platform')]}),
 ('0 chip and the Illumina HuHap550-Duo BeadChip.', {'entities': [(15, 23, 'platform')]}),
 ('DNA samples were genotyped using either the Illumina Human1M or 1M-Duo DNA Analysis BeadChips.', {'entities': [(44, 52, 'platform')]}),
 (" Genotyping was performed at the General Clinical Research Center's Phenotyping/Genotyping Laboratory at Cedars-Sinai using the Illumina 370CNV BeadChip system.", {'entities': [(128, 136, 'platform')]}),
 (" Genotyping was performed at the General Clinical Research Center's Phenotyping/Genotyping Laboratory at Cedars-Sinai using the Illumina 370CNV BeadChip system.", {'entities': [(128, 136, 'platform')]}),
 (' Genome-wide SNP genotyping on DNA extracted from blood samples was performed using Illumina Human610-Quadv1 chips (∼582 000 SNPs) or HumanCNV370-Quadv3 chips (∼351 000 SNPs).', {'entities': [(84, 92, 'platform')]}),
 (" We performed genotyping in BC_NHS, using the Illumina HumanHap550 array, as part of the National Cancer Institute's Cancer Genetic Markers of Susceptibility (CGEMS) Project ().", {'entities': [(46, 54, 'platform')]}),
 (' (i) The genotyping for the KS_NHS_HPFS was performed using the Illumina HumanHap610 Quad, and the imputation was performed in the same fashion as in the discovery set.', {'entities': [(64, 72, 'platform')]}),
 (" We performed genotyping in BC_NHS, using the Illumina HumanHap550 array, as part of the National Cancer Institute's Cancer Genetic Markers of Susceptibility (CGEMS) Project ().", {'entities': [(46, 54, 'platform')]}),
 (' (i) The genotyping for the KS_NHS_HPFS was performed using the Illumina HumanHap610 Quad, and the imputation was performed in the same fashion as in the discovery set.', {'entities': [(64, 72, 'platform')]}),
 (' Briefly, Illumina HumanHap 550K and 510S BeadChips were used for genotyping of DNA samples from all of the LCLs in the Genotype Shared Resource at Mayo Clinic.', {'entities': [(10, 18, 'platform')]}),
 (' The UK Stage I samples were genotyped using the Illumina Human Hap550 platform, while the UK and Australian Stage II samples were genotyped using a custom Infinium iSelect.', {'entities': [(49, 57, 'platform')]}),
 (' The non-European cases and controls from the MEC were genotyped on the Illumina 610 platform.', {'entities': [(72, 80, 'platform')]}),
 ("Twenty seven SNPs in a 400 kb region surrounding rs1337512 were genotyped on an Illumina BeadStation 500GX instrument using the Infinum II genotyping assays following manufacturer's recommendations.", {'entities': [(80, 88, 'platform')]}),
 (' Unrelated cases with a best-estimate diagnosis of bipolar I disorder were genotyped on the Illumina HumanHap550 array.', {'entities': [(92, 100, 'platform')]}),
 (' Unrelated cases with a best-estimate diagnosis of bipolar I disorder were genotyped on the Illumina HumanHap550 array.', {'entities': [(92, 100, 'platform')]}),
 (" Gender of 550 isolated, non-syndromic cleft palate (CP) cases in the international consortium study by recruitment siteThe Center for Inherited Disease Research (CIDR) genotyped DNA samples using Illumina's 610Quad platform and 99.1% passed CIDR quality control (QC) [].", {'entities': [(197, 205, 'platform')]}),
 ('Variants reaching genome-wide significance (p < 5\xa0× 10_−8 ) in the discovery set were tested for association with PH in the Mayo Genome Consortia (MayoGC), which includes Mayo Clinic patients with both EMR and GWAS data derived from prior studies on Illumina HumanHap550, Human610-Quad, and Human660W-Quad platforms.', {'entities': [(250, 258, 'platform')]}),
 (' Participants in the venous thromboembolism study were genotyped with the Illumina Human660W-Quad platform.', {'entities': [(74, 82, 'platform')]}),
 (' Participants in the pancreatic cancer study were genotyped with Illumina HumanHap550 and the Human 610-Quad chips.', {'entities': [(65, 73, 'platform')]}),
 (' Additionally, all markers were re-genotyped on >10% of samples typed with the Illumina platform, resulting in an observed mismatch in <0.5% of samples.', {'entities': [(79, 87, 'platform')]}),
 ('  In an analysis of 1000 samples, the comparison of the Illumina calls with the TaqMan assays showed a concordance rate of 100%.', {'entities': [(56, 64, 'platform')]}),
 (' The Illumina Infinium cluster plots for the two surrogate SNPs in the novel region in 18q12.3 (rs10775480 and rs10853535) are shown in Supplementary Material, Figure S4.', {'entities': [(5, 13, 'platform')]}),
 (' We genotyped a total of 15 925 individuals using either Illumina 317, 370 or 610 K chips at CIDR, deCode Genetics or the Finnish Genome Centre.', {'entities': [(57, 65, 'platform')]}),
 ("  In the discovery stage, we conducted the genotyping using Illumina Human 610-Quad Beadchips and the infiniumII assay following manufacturer's instructions.", {'entities': [(60, 68, 'platform')]}),
 ('98 and manually checked sample quality by means of B-allele frequency and LogR ratio), genotype cluster definitions for each SNP were determined using the ‘Cluster all SNPs’ option in Illumina BeadStudio Genotype module version 3.2.', {'entities': [(184, 192, 'platform')]}),
 (" In the discovery stage, we conducted the genotyping using Illumina Human 610-Quad Beadchips and the infiniumII assay following manufacturer's instructions.", {'entities': [(59, 67, 'platform')]}),
 ('98 and manually checked sample quality by means of B-allele frequency and LogR ratio), genotype cluster definitions for each SNP were determined using the ‘Cluster all SNPs’ option in Illumina BeadStudio Genotype module version 3.2.', {'entities': [(184, 192, 'platform')]}),
 (' GWAS genotyping, using the Illumina 370K array, was performed on a total of 6852 individuals selected from the BIGSIB and EDAC series (including N=336 parents); from a subsample of the NAG families that had previously been selected for 10cM microsatellite scans (), and a smaller number of additional alcohol dependent cases and controls from Cohorts 1 and 2. Additional GWAS data are included here for sample members who had been genotyped for other projects ().', {'entities': [(28, 36, 'platform')]}),
 (' Genotyping for the discovery study was performed with Illumina 1.2M (controls) or 670K (AAA) BeadChips.', {'entities': [(55, 63, 'platform')]}),
 (' eQTL analysis was performed with genotypes from circulating blood DNA (Illumina 610w-Quad BeadArrays).', {'entities': [(72, 80, 'platform')]}),
 ('SNP genotyping was performed with the Affymetrix Genome-Wide Human SNP Array 5.0 at the Vanderbilt Microarray Shared Resource at Vanderbilt University Medical Center, Nashville, TN, USA, using the standard protocol recommended by the manufacturer.', {'entities': [(38, 48, 'platform')]}),
 (' Controls had been genotyped previously using the Affymetrix® Genome-Wide Human SNP Array 6.0 platform and had passed genotyping quality controls measures analogous to those used for TGCT cases (see below).', {'entities': [(50, 60, 'platform')]}),
 (' We used the Affymetrix® Genome-Wide Human SNP Array 6.0 to obtain genotypes for TGCT cases.', {'entities': [(13, 23, 'platform')]}),
 (' Concordance between genotype calls obtained from the Affymetrix® chip and TaqMan assays for these four makers was 100%.', {'entities': [(54, 64, 'platform')]}),
 (' Genotyping was performed at the Broad Institute using the Affymetrix SNP 6.0 GeneChip and the Sequenom MassARRAY system for iPLEX assays ().', {'entities': [(59, 69, 'platform')]}),
 (' We started with 1,057 cases and 558 examined controls and studied 906,000 genotyped SNPs and 946,000 CNVs using the Affymetrix 6.0 GeneChip, which passed QC filters.', {'entities': [(117, 127, 'platform')]}),
 (' We added Myocardial Infarction Genetics Consortium (MIGen) shared controls (), which were genotyped on the same Affymetrix 6.0 GeneChip product, and conducted population stratification analyses using multidimensional scaling in PLINK ().', {'entities': [(113, 123, 'platform')]}),
 ('GWA genotype data were obtained by applying samples to an Affymetrix 6.0 SNP array.', {'entities': [(58, 68, 'platform')]}),
 ('  Seven hundred and seventy-five African-Americans from Maywood, IL, were genotyped with Affymetrix Genome-wide human SNP array 6.0, which provided genotype data at 909 622 SNPs in the human genome.', {'entities': [(89, 99, 'platform')]}),
 ('GWA genotype data were obtained by applying samples to an Affymetrix 6.0 SNP array.', {'entities': [(58, 68, 'platform')]}),
 (' Seven hundred and seventy-five African-Americans from Maywood, IL, were genotyped with Affymetrix Genome-wide human SNP array 6.0, which provided genotype data at 909 622 SNPs in the human genome.', {'entities': [(88, 98, 'platform')]}),
 ('01 in the Maywood and the Nigerian cohorts, respectively, in addition to the directly genotyped SNPs on the Affymetrix 6.0 array.', {'entities': [(108, 118, 'platform')]}),
 ('01 in the Maywood and the Nigerian cohorts, respectively, in addition to the directly genotyped SNPs on the Affymetrix 6.0 array.', {'entities': [(108, 118, 'platform')]}),
 (' Genotyping for 2745 patients with T2D and 3148 healthy controls from NHS and HPFS was done at the Broad Center for Genotyping and Analysis using the Affymetrix Genome-Wide Human 6.0 array (Santa Clara, CA, USA) and the Birdseed calling algorithm ().', {'entities': [(150, 160, 'platform')]}),
 (' ARIC samples were genotyped using the Affymetrix Genome-Wide Human 6.0 array.', {'entities': [(39, 49, 'platform')]}),
 (' FHS samples were genotyped using the Affymetrix 500K and MIPS 50K SNPs.', {'entities': [(38, 48, 'platform')]}),
 (' The RNA was extracted and purified, and aliquots were analyzed on Affymetrix GeneChip® Human Genome U133 Plus 2.0 microarrays following standard procedures.', {'entities': [(67, 77, 'platform')]}),
 (' Gene expression was assayed using standard Affymetrix procedures on samples from 9 different brain regions (prefrontal cortex, cerebral cortex, thalamus, visual cortex, hippocampus, amygdala, caudate, putamen and cerebellum) of 4 individuals (1 each male alcoholic, female alcoholic, male control, female control), obtained from the NIAAA-supported brain bank at the Tissue Resource Center located in the Neuropathology Unit of the Department of Pathology, University of Sydney, Australia.', {'entities': [(44, 54, 'platform')]}),
 (' To avoid SNPs with genotyping errors in the Gambian study, we used only SNPs on the Affymetrix platform for the Gambian data with minor allele frequency >41% and missingness <5% in both case and control cohorts, and with Hardy-Weinberg equilibrium P  ≥ 10_−7  in controls as the input for IMPUTE.', {'entities': [(85, 95, 'platform')]}),
 ('The beta-globin region was sequenced in 62 randomly selected Gambian control individuals who had previously been genotyped on the Affymetrix 500K array.', {'entities': [(130, 140, 'platform')]}),
 (' To avoid edge effects in haplotype phasing and imputation, the data for each sequenced sample was extended by including SNPs from the Affymetrix array flanking both ends of the sequenced region, creating a 1-Mb region centered on rs334 (at 5,204,808 in build 35) from 4,705,000 to 5,705,000 spanning 453 SNPs in total.', {'entities': [(135, 145, 'platform')]}),
 (' GHS participants were typed with the Affymetrix Genome-Wide Human SNP Array 6.0 as previously described.', {'entities': [(38, 48, 'platform')]}),
 (' Genotyping with the Affymetrix Mapping 250K Nsp and 250K Sty arrays was performed using the standard protocol recommended by the manufacturer.', {'entities': [(21, 31, 'platform')]}),
 (' Genotyping with the Affymetrix Mapping 250K Nsp and 250K Sty arrays was performed using the standard protocol recommended by the manufacturer.', {'entities': [(21, 31, 'platform')]}),
 ("All 10 DNA pools were genotyped in duplicate using the Affymetrix Genome-Wide Human SNP Array 6.0 according to the manufacturer's protocol.", {'entities': [(55, 65, 'platform')]}),
 (' Fluorescence intensities were quantitated using an Affymetrix array scanner 30007G.', {'entities': [(52, 62, 'platform')]}),
 (' Fluorescence intensities were quantitated using an Affymetrix array scanner 30007G.', {'entities': [(52, 62, 'platform')]}),
 (' Among the individuals examined, 1,412 were genotyped with the Affymetrix Mapping 500K Array Set.', {'entities': [(63, 73, 'platform')]}),
 (' Taking advantage of the relatedness among individuals in the SardiNIA sample, we conducted a second round of computational analysis to impute genotypes for analysis in an additional 2,893 individuals who were genotyped only with the Affymetrix Mapping 10K Array.', {'entities': [(234, 244, 'platform')]}),
 (' Briefly, 10 004 participants from the Ansung and Ansan cohorts were genotyped using the Affymetrix Genome-Wide Human SNP Array 5.0.', {'entities': [(89, 99, 'platform')]}),
 (' After checking DNA quality, 1225 individuals were genotyped using the Affymetrix Genome-Wide Human SNP Array 5.0.', {'entities': [(71, 81, 'platform')]}),
 (' As both KARE (stage I) and KIOM (stage II) data sets were genotyped using the same Affymetrix SNP 5.0 array platform, the two SNP data sets were combined to a data set of 9937 individuals in the joint analysis.', {'entities': [(84, 94, 'platform')]}),
 (' Controls were genotyped using the Affymetrix 6.0 array, at the Broad Institute National Center for Genotyping and Analysis.', {'entities': [(35, 45, 'platform')]}),
 ('For the stage 1 discovery analysis, we successfully genotyped 189 individuals with use of the Affymetrix GeneChip Human Mapping 500K Array Set (http://www.', {'entities': [(94, 104, 'platform')]}),
 (' SNP genotypes were called using the Affymetrix BRLMM algorithm []; the mean call rate for all SNPs was 98.5%.', {'entities': [(37, 47, 'platform')]}),
 (' For SNP quality assurance, we repeated the genotyping of 471,000 SNPs for 151 individuals with use of the Affymetrix Genome-Wide Human SNP Array (version 6.0; J.', {'entities': [(107, 117, 'platform')]}),
 (' To confirm ancestries, we combined our 189 sample genotypes with 30 HapMap reference samples [] were also genotyped on Affymetrix 500K arrays, including 10 individuals from each of the following populations: Yoruba in Ibadan, Nigeria; Japanese in Tokyo, Japan, and Chinese in Beijing, China; and Utah residents with ancestry from northern and western Europe.', {'entities': [(120, 130, 'platform')]}),
 (' Genotyping was performed using the Affymetrix Genome-Wide Human SNP Array, version 6.0.', {'entities': [(36, 46, 'platform')]}),
 (' Thus, data from Sardinian individuals genotyped with the Affymetrix Mapping 500K Array Set (N = 1,412) was used to infer missing genotypes in their offspring or siblings genotyped with the 10K Array Set (N =2,893), for a total of 4,305 samples available for GWA analyses (personality data were available for 3,972 of these participants).', {'entities': [(58, 68, 'platform')]}),
 (' RNA quality was tested using an Agilent 2100 Bioanalyzer, followed by hybridization to Affymetrix U133 Plus 2.0 Gene-Chips.', {'entities': [(88, 98, 'platform')]}),
 (' DNA was extracted from blood, quantitated and genotyped by using Affymetrix 6.0 microarrays according to the manufacturer’s instructions.', {'entities': [(66, 76, 'platform')]}),
 (' Genotypes for each individual passed Affymetrix quality control metrics with a contrast quality control threshold >0.4 and provided calls for >97% of SNP genotypes.', {'entities': [(38, 48, 'platform')]}),
 (' Each sample was genotyped with the Affymetrix GeneChip Human Mapping 100\u2009K array pair (Santa Clara, CA, USA), as described in the GeneChip Human Mapping 100\u2009K Assay Manual.', {'entities': [(36, 46, 'platform')]}),
 (' Genotype calling was performed using the BRLMM algorithm of the Affymetrix GeneChip Genotyping Analysis Software (GTYPE) version 4.1.', {'entities': [(65, 75, 'platform')]}),
 (' In total, 352 samples from the Saami subjects were genotyped with the Affymetrix 100\u2009K array.', {'entities': [(71, 81, 'platform')]}),
 (" Briefly, SNP genotyping was performed using the Affymetrix Genomewide Human SNP Array 5.0, according to the manufacturer's standard protocol.", {'entities': [(49, 59, 'platform')]}),
 ('All GWA studies were genotyped using the Affymetrix GeneChip 500K array set, and genotypes were called using the BRLMM algorithm.', {'entities': [(41, 51, 'platform')]}),
 (' Genotype data from B58C was obtained using an Affymetrix GeneChip Human Mapping 500K Array.', {'entities': [(47, 57, 'platform')]}),
 (' In brief, genome-wide SNPs were measured using Affymetrix SNP array 6.0 in an initial set of 8861 participants of European ancestry.', {'entities': [(48, 58, 'platform')]}),
 (' The ARIC cohort did not have imputed data on those of African ancestry so testing was restricted to successfully genotyped SNPs on their Affymetrix 6.0 chip that had an average weighted MAF of at least 0.', {'entities': [(138, 148, 'platform')]}),
 (' Imputed genotypes were not determined in ARIC individuals of African ancestry and genotypes available for analysis were restricted to successfully genotyped SNPs on the Affymetrix 6.0 chip.', {'entities': [(170, 180, 'platform')]}),
 ('Of the 116 201 SNPs on the Affymetrix GeneChip Human Mapping 100K array set, the number of SNPs suitable for statistical analysis was reduced to 102 334 in black subjects (88.0% of total) and to 95 221 in white subjects (81.', {'entities': [(27, 37, 'platform')]}),
 ('DNA was extracted and genotyped for consenting FHS participants with the Affymetrix 500K array and an additional gene-focused 50K array as part of the SNP Health Association Resource (SHARe) project with final genotypes available from 8482 participants.', {'entities': [(73, 83, 'platform')]}),
 (' Specifically, 1412 were genotyped with the 500K Affymetrix Mapping Array Set and 3,329 with the 10K Mapping Array Set, with 436 individuals genotyped with both arrays.', {'entities': [(49, 59, 'platform')]}),
 (' The BRLMM algorithm from Affymetrix was used to make genotype calls, and the average genotyping call rate was 99.1%.', {'entities': [(26, 36, 'platform')]}),
 ('The discovery sample consisted of 1221 healthy donors from the UK Blood Services Common Control (UKBS-CC1) genotyped with the Affymetrix (Santa Clara, CA) 500K Array.', {'entities': [(126, 136, 'platform')]}),
 (' All 17,000 samples were genotyped with the GeneChip 500K Mapping Array Set (Affymetrix chip), which comprises 500,568 SNPs, as described in Methods.', {'entities': [(77, 87, 'platform')]}),
 (' Cross-platform comparison showed CHIAMO to outperform BRLMM (the standard Affymetrix algorithm) by having an error rate under 0.2% (), and comparison of 10_8  duplicate genotypes in our study gave a discordance rate of 0.', {'entities': [(75, 85, 'platform')]}),
 (' Therefore, we expect genome coverage with the Affymetrix 500K set in this study to be similar to that estimated for the HapMap CEU panel.', {'entities': [(47, 57, 'platform')]}),
 (' For polymorphic SNPs on the Affymetrix chip, we performed trend tests (1 degree of freedom) and general genotype tests (2 degrees of freedom, referred to as genotypic) between each case collection and the pooled controls, and calculated analogous Bayes factors.', {'entities': [(29, 39, 'platform')]}),
 (' One of the signals for which we failed to obtain evidence of replication (APOE  in CAD) is poorly tagged by the Affymetrix 500K chip.', {'entities': [(113, 123, 'platform')]}),
 (' This is the consequence of several factors including: less-than-complete coverage of common variation genome-wide on the Affymetrix chip; poor coverage (by design) of rare variants, including many structural variants (thereby reducing power to detect rare, penetrant, alleles); difficulties with defining the full genomic extent of the gene of interest; and, despite the sample size, relatively low power to detect, at levels of significance appropriate for genome-wide analysis, variants with modest effect sizes (odds ratio (OR) < 1.2).', {'entities': [(122, 132, 'platform')]}),
 (' Cluster plots for this SNP seem good, but it is surrounded by recombination hotspots and has no other SNPs on the Affymetrix chip with r _2 >0.1 ().', {'entities': [(115, 125, 'platform')]}),
 (' The SNP in SLC30A8  associated with T2D in the French report (rs13266634) is poorly correlated with SNPs on the Affymetrix chip (r _2 <0.01), and extensive recombination events in the region limit the value of data-imputation methods.', {'entities': [(113, 123, 'platform')]}),
 (' Genotyping was performed using GeneChip 500K arrays at the Affymetrix Services Lab (California): arrays not passing the 93% call rate threshold at P =0.33 with the Dynamic Model algorithm were repeated.', {'entities': [(60, 70, 'platform')]}),
 ("  We first genotyped the whole-genome SNPs of 425 case and 301 control samples on an Affymetrix GeneChip Mapping 500K Array Set, following the manufacturer's instructions.", {'entities': [(85, 95, 'platform')]}),
 (" We first genotyped the whole-genome SNPs of 425 case and 301 control samples on an Affymetrix GeneChip Mapping 500K Array Set, following the manufacturer's instructions.", {'entities': [(84, 94, 'platform')]}),
 (' To validate the genotyping accuracy in stages 1 and 2, we genotyped the 216 SNPs in 104 (52 case and 52 control) samples using both an Affymetrix 500K Array Set and the iSelect system and analyzed the genotype concordance between the 2 systems (see SI Text ).', {'entities': [(136, 146, 'platform')]}),
 (' To validate the genotyping accuracy in stages 1 and 2, we genotyped the 216 SNPs in 104 (52 case and 52 control) samples using both an Affymetrix 500K Array Set and the iSelect system and analyzed the genotype concordance between the 2 systems (see SI Text ).', {'entities': [(136, 146, 'platform')]}),
 ('1% Tween 20), in turn, on an Affymetrix Fluidics Station FS450. Then they were stained subsequently with the Streptavidin Phycoerythrin (SAPE, 10 μg/ml) and Anti-streptavidin antibody.', {'entities': [(29, 39, 'platform')]}),
 (' The stained arrays were scanned with an Affymetrix GeneChip_®  3000 7G scanner at 0.7 μm solution.', {'entities': [(41, 51, 'platform')]}),
 (' We obtained NIMH genotypes from previously generated GWA data on the Affymetrix 500K platform through a formal application process.', {'entities': [(70, 80, 'platform')]}),
 (' Genotyping for 59 patients in the validation cohort was performed by using the Affymetrix Genome-Wide Human SNP Array 6.0 based on the Birdseed genotype-calling algorithm, which overlaps with 482,251 of the 500,568 SNPs on the 500K chip.', {'entities': [(80, 90, 'platform')]}),
 (' Genotyping for participants in the Wellcome Trust Case Control Consortium study was performed as reported, using the Affymetrix 500K Mapping Array sets.', {'entities': [(118, 128, 'platform')]}),
 (' The GAIN participants were analyzed by using the Affymetrix Genome-Wide Human SNP Array 6.0.', {'entities': [(50, 60, 'platform')]}),
 ('_,   Gene expression data were analyzed by using the Affymetrix MAS5.0 algorithm.', {'entities': [(53, 63, 'platform')]}),
 ('       A genome-wide association study for LDL-C was carried out in 2346 people of the Island of Kosrae, Federated States of Micronesia using SNPs from the Affymetrix 500k platform.', {'entities': [(156, 166, 'platform')]}),
 (' These individuals were homozygous for the major (n=9) or minor allele (n=9) at rs3846662 and the three proxy SNPs from the Affymetrix 500k array (rs3846663, rs7703051 and rs12654264).', {'entities': [(124, 134, 'platform')]}),
 (' Genotyping was performed using the Affymetrix Genome-Wide Human SNP Array 6.0.', {'entities': [(36, 46, 'platform')]}),
 (' Genotyping was performed using the Affymetrix 500K Array Set.', {'entities': [(36, 46, 'platform')]}),
 (' Genotyping was performed using the Affymetrix 500K Mapping Array Set using the call algorithm CHIAMO as implemented by the WTCCC.', {'entities': [(36, 46, 'platform')]}),
 (' Biotinylated cRNA was hybridized to the Affymetrix GeneChip HG-U133 Plus 2.0 arrays, containing probes for approximately 22,634 genes, at the CCHMC Digestive Health Center Microarray Core.', {'entities': [(41, 51, 'platform')]}),
 (' The images were captured using Affymetrix GeneChip Scanner 3000. We normalized data to allow for array-to-array comparisons, and we detected differences between groups in GeneSpring with significance at the 0.', {'entities': [(32, 42, 'platform')]}),
 (' Both cohorts were genotyped using Affymetrix GeneChip Mapping 500K Array.', {'entities': [(35, 45, 'platform')]}),
 ('Genotyping in the SHARe study (,) was carried out using the Affymetrix (Santa Clara, CA, USA) GeneChip Human Mapping 500K mapping array and supplemental 50K mapping array (HuGeneFocused50K) with gene-centric and coding SNPs.', {'entities': [(60, 70, 'platform')]}),
 ('Participants of the HAPI Heart Study were genotyped with the use of the Affymetrix GeneChip® Human Mapping 500K Array set.', {'entities': [(72, 82, 'platform')]}),
 (' The nonsynonymous SNP, SLCO1B1  T521C (rs4149056) was not represented on the Affymetrix arrays and was independently genotyped (DNAPrint Genomics, Sarasota, FL); call rates were more than 97% for this SNP.', {'entities': [(78, 88, 'platform')]}),
 (' We genotyped the remaining 979 samples using the Affymetrix Genome-Wide Human SNP Array 5.0.', {'entities': [(50, 60, 'platform')]}),
 (' Genotyping was performed with the Affymetrix 10K and 500K Mapping Arrays in 3,329 and 1,412 individuals respectively (436 subjects were genotyped with both chips).', {'entities': [(35, 45, 'platform')]}),
 (' PWV was assessed with the Complior®SP device (Artech Medical, Pantin, France) before the interventions were administered, and genotyping was performed with an Affymetrix 500K chip.', {'entities': [(160, 170, 'platform')]}),
 (' Whole genome genotyping was performed using the Affymetrix Genechip® Human Mapping 500K Array Set, which included 238,304 SNPs from a StyI  chip and 262,264 SNPs from an NspI  chip.', {'entities': [(49, 59, 'platform')]}),
 (' Genotyping for replication testing and for evaluation against CHD was performed using KASPar (LOLIPOP), Sequenom (INTERHEART, PROCARDIS), TaqMan (ISIS, WTCCC), or Affymetrix mapping arrays (GerMIFS1&2, WTCCC).', {'entities': [(164, 174, 'platform')]}),
 ("Samples were genotyped at Affymetrix's service laboratory on the Genome-Wide Human SNP Array 6.0.", {'entities': [(26, 36, 'platform')]}),
 ('html), adapted for Affymetrix 6.0 SNP data.', {'entities': [(19, 29, 'platform')]}),
 ('2M chip as part of a separate WTCCC2 project, and the 50,000 SNPs which are shared between that platform and the Affymetrix 6.0 (used in this study) were used to evaluate genotype accuracy.', {'entities': [(113, 123, 'platform')]}),
 (' A total of 137 cases which passed the DNA quality check were entered into the GWAS using Affymetrix Genome-Wide Human SNP Array 5.0.', {'entities': [(90, 100, 'platform')]}),
 (' The same platform (Affymetrix Genome-Wide Human SNP Array 5.0) was used for the whole-genome scan of the controls.', {'entities': [(20, 30, 'platform')]}),
 ('Among the 500,568 SNPs present in Affymetrix Whole Genome Human SNP Array 5.0, 440,734 SNPs were accessible after excluding hidden SNPs.', {'entities': [(34, 44, 'platform')]}),
 (' Genome-wide genotyping was performed using the Affymetrix Genome-Wide Human 6.0 array.', {'entities': [(48, 58, 'platform')]}),
 ('0 software to impute SNPs that are not covered in Affymetrix 6.0 chip.', {'entities': [(50, 60, 'platform')]}),
 (' As part of this public-private partnership, DNA from 1,879 available participants of GoKinD were submitted for genotyping on the Affymetrix 5.0 500K SNP Array by the GAIN genotyping laboratory at the Eli and Edythe L.', {'entities': [(130, 140, 'platform')]}),
 (' Locus-specific imputation was performed to examine 12 additional SNPs not genotyped on the Affymetrix 5.0 platform but that had previously been reported to be associated with DN.', {'entities': [(92, 102, 'platform')]}),
 ('Our analysis of GWA data from the GoKinD collection included 359,193 SNPs genotyped on the Affymetrix 5.0 500K SNP Array, a platform that offers approximately 76% coverage of common variation across the entire genome.', {'entities': [(91, 101, 'platform')]}),
 (' Genotyping was done using the Affymetrix Genome-Wide Human 6.0 array and the Birdseed calling algorithm ().', {'entities': [(31, 41, 'platform')]}),
 (' Genotyping was done using the Affymetrix Genome-Wide Human 6.0 array and the Birdseed calling algorithm ().', {'entities': [(31, 41, 'platform')]}),
 (' The replication samples from NHS were genotyped at Rosetta/Merck using the Affymetrix Genome-Wide Human 6.0 array and the Birdseed calling algorithm ().', {'entities': [(76, 86, 'platform')]}),
 (' Affymetrix processed more than 99% of the samples.', {'entities': [(1, 11, 'platform')]}),
 (' Genotypes were called using the Affymetrix Birdseed v2 algorithm.', {'entities': [(33, 43, 'platform')]}),
 ('Genotyping was done using the Affymetrix Genome-Wide Human SNP Array 6.0 ().', {'entities': [(30, 40, 'platform')]}),
 (', of the Laboratory for Genetic Diversity (LGD) at the National Cancer Institute, and consisted of 1,877 males genotyped on the Affymetrix 6.0 platform.', {'entities': [(128, 138, 'platform')]}),
 (', of the University of Washington (herein referred to as the Mullins data set) and consisted of 191 males genotyped on the Affymetrix 500K platform.', {'entities': [(123, 133, 'platform')]}),
 (', of the Laboratory for Genetic Diversity (LGD) at the National Cancer Institute, and consisted of 1,877 males genotyped on the Affymetrix 6.0 platform.', {'entities': [(128, 138, 'platform')]}),
 (', of the University of Washington (herein referred to as the Mullins data set) and consisted of 191 males genotyped on the Affymetrix 500K platform.', {'entities': [(123, 133, 'platform')]}),
 (' After sample processing, genome-wide genotyping was performed using the Affymetrix Genome Wide Human SNP Array 6.0 ().', {'entities': [(73, 83, 'platform')]}),
 ('07) for SNPs from Affymetrix 6.0, and 0.', {'entities': [(18, 28, 'platform')]}),
 (' Genotyping was done using the Affymetrix Genome-Wide Human 6.0 Array (Santa Clara, CA, USA).', {'entities': [(31, 41, 'platform')]}),
 ('Genotyping was performed on the Affymetrix Genome-Wide Human SNP Array 6.0 platform.', {'entities': [(32, 42, 'platform')]}),
 (' Briefly, germline DNA was genotyped using either the Affymetrix GeneChip human Mapping 500K sets or SNP6.0 array.', {'entities': [(54, 64, 'platform')]}),
 (' We included all MESA participants who underwent GWAS genotying using the Affymetrix 6.0 SNP array as part of the MESA SNP Health Association Resource (SHARe) (study accession phs000209, http://www.', {'entities': [(74, 84, 'platform')]}),
 (' Affymetrix performed plate-based genotype calling using Birdseed v2. Sample QC was based on call rates and contrast QC (cQC) statistics.', {'entities': [(1, 11, 'platform')]}),
 ("The SFBCS () and the NC-BCFR () study samples were genotyped with the Affymetrix 6.0 array according to the manufacturer's instructions (https://www.", {'entities': [(70, 80, 'platform')]}),
 (' SNPs on the Y\xa0chromosome and Affymetrix quality-control (QC) probes were excluded from analysis (n = 3,280).', {'entities': [(30, 40, 'platform')]}),
 ('html), adapted for Affymetrix 6.0 SNP data (,).', {'entities': [(19, 29, 'platform')]}),
 (' Using a label corresponding to the genotyping center as a covariate gave a similar λ to just using the data that was genotyped at Affymetrix (λ = 1.095, λ = 1.', {'entities': [(131, 141, 'platform')]}),
 (' Genotypes from the Affymetrix GeneChip® Human Mapping 6.0 Array Sets were suitable for statistical analyses in the 198 White and 193 African Americans treated with candesartan.', {'entities': [(20, 30, 'platform')]}),
 (' Genotypes from the Affymetrix GeneChip® Human Mapping 500K Array Sets were suitable for statistical analyses in 196 White and 194 African Americans treated with hydrochlorothiazide (please see http://hyper.', {'entities': [(20, 30, 'platform')]}),
 (' Data from TCGA on RCC cases were genotyped using the Affymetrix Genome-Wide Human SNP Array 6.0.', {'entities': [(54, 64, 'platform')]}),
 (' Imputation of SNPs in the 1000 Genomes dataset not represented on the Affymetrix SNP 6.0 array was performed on each ancestral group independently using MACH1.', {'entities': [(71, 81, 'platform')]}),
 ('In the four CARe cohorts, individual estimates of the proportion of African relative to European ancestry was calculated from 3192 independent ancestry informative markers included on the Affymetrix 6.0 array using the Markov Chain Monte Carlo algorithm implemented in ANCESTRYMAP as in previous studies.', {'entities': [(188, 198, 'platform')]}),
 (' All the individuals were genotyped using Affymetrix GeneChip 500K arrays.', {'entities': [(42, 52, 'platform')]}),
 (' Using the SNP map annotations provided by Affymetrix 5.0 GeneChip as a reference (https://www.', {'entities': [(43, 53, 'platform')]}),
 (' Briefly, genotyping was done using Affymetrix Genome-Wide Human 6.0 array and genotypes were called using the Birdseed algorithm for a total of 906,600 single nucleotide polymorphisms (SNPs) ().', {'entities': [(36, 46, 'platform')]}),
 (' The final hybrid dataset included 2,543,887 SNPs, of which 584,029 were initially genotyped in the GOLDN population using the Affymetrix 6.0 chip ().', {'entities': [(127, 137, 'platform')]}),
 (' This group was genotyped using the Affymetrix 5.0 GeneChip Array or the 500K Mapping Array.', {'entities': [(36, 46, 'platform')]}),
 (' Individuals were genotyped on the Affymetrix 6.0 GeneChip Array.', {'entities': [(35, 45, 'platform')]}),
 (' Individuals were genotyped using the Affymetrix 6.0 GeneChip array.', {'entities': [(38, 48, 'platform')]}),
 (' Amongst the Hutterites, rs9469220, rs7751374, rs10124954, rs537526, and rs16977747 were genotyped on the Affymetrix 6.0 GeneChip, and rs613614, rs2101567, rs9314043, and rs11075734 were used as genotype proxies for rs321588, rs2363709, rs13361473, and rs6499255, respectively.', {'entities': [(106, 116, 'platform')]}),
 (' () dataset described 218 glioblastoma expression samples including 132 samples from three previously published datasets as well as 86 new samples assembled into a single, unified dataset using Affymetrix U133A.', {'entities': [(194, 204, 'platform')]}),
 (' () dataset contains 75 glioblastoma expression samples using the Affymetrix U133. Normalized expression values using the standard RMA method for the Lee and Murat datasets were downloaded from the NCBI GEO database (GSE13041 and GSE7696).', {'entities': [(66, 76, 'platform')]}),
 (' The TCGA dataset () has 326 primary glioblastoma expression samples using the Affymetrix U133A expression platform.', {'entities': [(79, 89, 'platform')]}),
 (' () dataset described 218 glioblastoma expression samples including 132 samples from three previously published datasets as well as 86 new samples assembled into a single, unified dataset using Affymetrix U133A.', {'entities': [(194, 204, 'platform')]}),
 (' () dataset contains 75 glioblastoma expression samples using the Affymetrix U133. Normalized expression values using the standard RMA method for the Lee and Murat datasets were downloaded from the NCBI GEO database (GSE13041 and GSE7696).', {'entities': [(66, 76, 'platform')]}),
 (' The TCGA dataset () has 326 primary glioblastoma expression samples using the Affymetrix U133A expression platform.', {'entities': [(79, 89, 'platform')]}),
 (' Ninety-seven genes could be reliably assigned a probe on the Affymetrix HG_U133AAofAv2 array (); these transcripts were, on average, expressed at higher levels in late erythroblasts (or the precursors of red blood cells, EB3–EB5) compared to other transcripts in the same cell type (P  <0.01 after Bonferroni correction; ).', {'entities': [(62, 72, 'platform')]}),
 (' We performed high-density genotyping using the Affymetrix 6.0 chips on 1276 cases and 715 controls following the recommended protocol, with genotype calling using the Birdseed program in APT BirdSuite 1.', {'entities': [(48, 58, 'platform')]}),
 (' Only SNPs included in the Affymetrix 6.0 SNP arrays were selected for Stage-II evaluation.', {'entities': [(27, 37, 'platform')]}),
 ('005 in the SBCS GWA scan data for SNPs on Affymetrix 6.0 array (,).', {'entities': [(42, 52, 'platform')]}),
 ('org/) in each of the 96-well plates for Affymetrix SNP Array 6.0 genotyping.', {'entities': [(40, 50, 'platform')]}),
 (' To compare the consistency between Affymetrix 6.0 and Sequenom platforms, we also genotyped 124 samples included in Stage I in the Stage II Sequenom genotyping; the concordance rate was 98.', {'entities': [(36, 46, 'platform')]}),
 (' Data from the SeBCS phase I (SeBCS-I) analyzed in Stage IV were extracted from GWA scan data generated using the Affymetrix Genome-Wide Human SNP Array 6.0.', {'entities': [(114, 124, 'platform')]}),
 ('5% between Sequenom and Affymetrix 6.0 genotyping.', {'entities': [(24, 34, 'platform')]}),
 (' Of the 909,622 markers on the Affymetrix 6.0 Array, 336,734 were deemed unusable due to lack of polymorphism, severe deviation from Hardy-Weinberg equilibrium (P  < 1 × 10_−5 ), low-yield (<95% in either cases or controls) or with minor allele frequencies below 0.', {'entities': [(31, 41, 'platform')]}),
 ('Affymetrix Power Tools (APT), version 1.10.', {'entities': [(0, 10, 'platform')]}),
 (' The transcriptome-wide expression levels in two human primary cells (brain and PBMC) in the Duke samples () were assessed using Affymetrix Human ST 1.0 exon arrays.', {'entities': [(129, 139, 'platform')]}),
 ('_–  The sixth stratum (BWH/TT) is based on data from our previous study enriched with additional 1453 MS cases and 2176 controls, with all samples genotyped on the Affymetrix GeneChip 6.0 platform.', {'entities': [(164, 174, 'platform')]}),
 (' We collected RNA expression data with an Affymetrix U133 v2.0 array from peripheral blood mononuclear cells (PBMCs) of 228 subjects with Relapsing Remitting (RR) MS or CIS.', {'entities': [(42, 52, 'platform')]}),
 (' We used the Affymetrix Genome-Wide Human SNP Array 6.0 to obtain genotypes for the NSHL cases and GAIN controls.', {'entities': [(13, 23, 'platform')]}),
 (' We used the Affymetrix Genome-Wide Human SNP Array 6.0 to obtain genotypes for the NSHL cases and GAIN controls.', {'entities': [(13, 23, 'platform')]}),
 (" All participants were genotyped on the Affymetrix 6.0 platform; additional details about the height consortium are described in N'Diaye et al .", {'entities': [(40, 50, 'platform')]}),
 ('Genome-wide genotyping of single nucleotide polymorphisms (SNPs) was performed on the Affymetrix Genome-Wide Human Array 6.0 chip in a subset of European ancestry patients in GeneBank.', {'entities': [(86, 96, 'platform')]}),
 (' Briefly, samples were genotyped and analysed using the Affymetrix Genome-Wide Human 6.0 array (Santa Clara, CA, USA) and the Birdseed calling algorithm.', {'entities': [(56, 66, 'platform')]}),
 (' A total of 906,600 SNPs were genotyped using the Affymetrix Genome-Wide Human 6.0 array and the Birdseed calling algorithm [].', {'entities': [(50, 60, 'platform')]}),
 (' Of the 545 patients, 316 cases and 229 controls were genotyped using the Affymetrix 500K SNP array (443,816 SNPs).', {'entities': [(74, 84, 'platform')]}),
 ('In Stage 1, using the 500K Affymetrix SNP array, 443,816 SNPs were analyzed.', {'entities': [(27, 37, 'platform')]}),
 (' SNPs that were located on the Y chromosome or were Affymetrix quality control probes (not intended for analysis) were excluded (n  = 3280).', {'entities': [(52, 62, 'platform')]}),
 (' Genotyping of GWAS samples was performed at the Center for Inherited Disease Research using 1 μg of genomic DNA on Affymetrix Genome-wide Human SNP array 6.0.', {'entities': [(116, 126, 'platform')]}),
 (' Genotyping of GWAS samples was performed at the Center for Inherited Disease Research using 1 μg of genomic DNA on Affymetrix Genome-wide Human SNP array 6.0.', {'entities': [(116, 126, 'platform')]}),
 ('GWAS of the CAPS population was performed using Affymetrix 5.0 chip.', {'entities': [(48, 58, 'platform')]}),
 ('Framingham participants were genotyped using the Affymetrix (Santa Clara, CA) GeneChip Human Mapping 500K Array Set, which was comprised of two arrays generating approximately 262,000 SNPs with Nsp arrays and 238,000 SNPs with Sty arrays.', {'entities': [(49, 59, 'platform')]}),
 (' An additional Affymetrix 50K Array (HuGeneFocused50K) with gene-centric and coding SNPs was also genotyped for a total of approximately 550K SNPs.', {'entities': [(15, 25, 'platform')]}),
 (' Genomic DNA samples were genotyped primarily using the Affymetrix Genome-Wide Human SNP Array 6.0.', {'entities': [(56, 66, 'platform')]}),
 (' We also included 65 participants who were genotyped by using the Affymetrix 6.0 array on the Sequenom genotyping platform and found 100% consistency for data generated on these two platforms.', {'entities': [(66, 76, 'platform')]}),
 ("Genome-wide SNP genotyping was performed using the Affymetrix Human SNP Array 5.0 following the manufacture's protocol.", {'entities': [(51, 61, 'platform')]}),
 ('DNA from ROS and MAP subjects was extracted from whole blood, lymphocytes or frozen post-mortem brain tissue and genotyped on the Affymetrix Genechip 6.0 platform at either the Broad Institute’s Center for Genotyping (n=1,204) or the Translational Genomics Research Institute (n=674).', {'entities': [(130, 140, 'platform')]}),
 ('Gene expression levels were quantified using mRNA derived from peripheral blood mononuclear cells (PBMCs) of 228 subjects of European ancestry with Relapsing Remitting (RR) Multiple Sclerosis (MS) using an Affymetrix Human Genome U133 Plus 2.0.', {'entities': [(206, 216, 'platform')]}),
 (' DNA from each individual was genotyped on the Affymetrix GeneChip 6.0 platform as a part of a case-control multiple sclerosis meta-analysis ().', {'entities': [(47, 57, 'platform')]}),
 ('  DNA was genotyped on the Affymetrix 6.0 array as previously reported (, ), and 597,198 SNPs passed quality control filters (SNP call rate > 95%, minor allele frequency > 5%, Hardy–Weinberg disequilibrium P  < 1 × 10_−6 ) and were merged with HapMap 3 reference populations.', {'entities': [(27, 37, 'platform')]}),
 (' DNA was genotyped on the Affymetrix 6.0 array as previously reported (, ), and 597,198 SNPs passed quality control filters (SNP call rate > 95%, minor allele frequency > 5%, Hardy–Weinberg disequilibrium P  < 1 × 10_−6 ) and were merged with HapMap 3 reference populations.', {'entities': [(26, 36, 'platform')]}),
 (' For gene expression profiling by Affymetrix U95Av2 microarrays, the expression measures for each probe set was extracted and normalized using robust multi-array average protocols from raw CEL files.', {'entities': [(34, 44, 'platform')]}),
 (' Genetic data for all stages were obtained via the Affymetrix 6.0 array for 1,264 African American and 1,358 Caucasian HyperGEN and 989 GENOA participants.', {'entities': [(51, 61, 'platform')]}),
 (' Genotyping was performed using the Affymetrix 500K array (OHGS_A, WTCCC), 6.0 array (OHGS_CCGB_B, ITH) or Axiom array (DUKE).', {'entities': [(36, 46, 'platform')]}),
 (' Genotyping was performed using the Affymetrix 500K (GerMIFS1) and 6.0 (GerMIFS2, PennCath, MedStar, OHGS_CCGB_S) arrays.', {'entities': [(36, 46, 'platform')]}),
 ('_,   Imputation with HLA*IMP is performed using pre-defined sets of SNPs for each of several common commercial microarrays, including the Affymetrix 500K and 6.0, but not the Axiom array.', {'entities': [(138, 148, 'platform')]}),
 (' TwinsUK: Framingham Osteoarthritis Study: samples from 9274 individuals were genotyped using the Affymetrix GeneChip® Human Mapping 500K array set and the 50K supplemental array set focused on coding SNPs and SNPs tagging protein-coding genes (Santa Clara, California) as part of the SHARE initiative.', {'entities': [(98, 108, 'platform')]}),
 ('For the initial phase, genotyping was done at the Affymetrix Service Center using the Genome-Wide Human SNP Array 6.0.', {'entities': [(50, 60, 'platform')]}),
 (' All assays used the Affymetrix GeneChip Genome-Wide Human SNP Array 5.0, with hybridization and scanning at the ASL.', {'entities': [(21, 31, 'platform')]}),
 (' If the original candidate SNP was not genotyped on our array, we evaluated the imputed genotype, which was obtained by imputing all the HapMap release 22 SNPs (combined panel of ethnic groups: CEU [Utah residents with Northern and Western European ancestry from the CEPH collection], YRI [Yoruba in Ibadan], CHB [Han Chinese in Beijing], and JPT [Japanese in Tokyo]) that were not genotyped on the Affymetrix 5.0 array using IMPUTE software (https://mathgen.', {'entities': [(399, 409, 'platform')]}),
 ('Of the 553 Hutterite husbands whose wives were interviewed, 269 with DNA available were genotyped with one of three Affymetrix SNP arrays: GeneChip 500K Mapping Array (n = 158), Genome-Wide Human SNP Array 5.0 (n = 14), or Genome-Wide Human SNP Array 6.', {'entities': [(116, 126, 'platform')]}),
 (' Genotyping was performed using the Affymetrix Gene Chip Human Mapping 500K Array Set at the Broad Institute of Harvard and MIT using standard protocols and quality control, and addressing potential population stratification as previously described (, ).', {'entities': [(36, 46, 'platform')]}),
 (' Genome-wide genotyping was performed using the Affymetrix_®  Genome-Wide Human SNP Array 6.0.', {'entities': [(48, 58, 'platform')]}),
 ('DNA was extracted from blood and genotyped on the Affymetrix 6.0 array, as previously reported_,  .', {'entities': [(50, 60, 'platform')]}),
 ('GWAS genotyping was performed by Affymetrix (Santa Clara, CA) using a Human SNP Array 6.0.', {'entities': [(33, 43, 'platform')]}),
 (' Participants’ DNA was extracted from blood samples drawn from an antecubital vein, and genotyping was performed with the Affymetrix Genome-Wide Human SNP Array 6.0 chip.', {'entities': [(122, 132, 'platform')]}),
 (' We applied the same quality control criteria as with the Affymetrix 6.0 array data.', {'entities': [(58, 68, 'platform')]}),
 (' In total, we evaluated a total of 736,996 autosomal SNPs (651,201 from the Affymetrix array and 85,795 non-overlapping SNPs from the Immunochip) for association with the AbPA response to AVA.', {'entities': [(76, 86, 'platform')]}),
 (' Hybridization probes were prepared with precautions to avoid contamination, as described (Affymetrix Assay 6.0, []).', {'entities': [(91, 101, 'platform')]}),
 (' Briefly, genotyping was performed with the Affymetrix Genome-Wide Human SNP Array 5.0.', {'entities': [(44, 54, 'platform')]}),
 (' Genotypes were called using Birdseed version 2; Affymetrix Power Tools (APT) 1.10.', {'entities': [(49, 59, 'platform')]}),
 (' Genotypes were called using Birdseed version 2; Affymetrix Power Tools (APT) 1.10.', {'entities': [(49, 59, 'platform')]}),
 (' Within the Affymetrix 6.0 chip, there were 2906 duplicate SNPs, among which we observed > 99.', {'entities': [(12, 22, 'platform')]}),
 (' Genotypes were called using BRLMM algorithm (Affymetrix, Inc) for 500K and Birdseed Algorithm for Genome-Wide Human SNP Array 6.0.', {'entities': [(46, 56, 'platform')]}),
 ('DNA was extracted from lymphoblast cell lines[] and run on the Affymetrix genome-wide human SNP array 6.0 genotyping platform.', {'entities': [(63, 73, 'platform')]}),
 ('4) were genotyped for 934,968 SNPs using Affymetrix Power Tools (apt-probeset-genotype 1.10.', {'entities': [(41, 51, 'platform')]}),
 (' Autosomal perfect-match SNPs supported by Affymetrix (n  = 868,157) were evaluated for Mendelian inheritance in CEPH trios (389 dropped), SNP call rates of >95% (39,220 dropped), Hardy Weinburg equilibrium (HWE; P  > .', {'entities': [(43, 53, 'platform')]}),
 (' For the Molecular Genetics of Schizophrenia (MGS2) genome wide association study (GWAS) of schizophrenia (), we genotyped 3,827 (2,817 EA and 1,010 AA) control samples with the Affymetrix 6.0 array, selected for eligibility based on previous laboratory study of genotypic ancestral background and DNA quality.', {'entities': [(178, 188, 'platform')]}),
 ('As previously described in more detail (), DNA samples were genotyped using the Affymetrix 6.0 array at the Broad Institute.', {'entities': [(80, 90, 'platform')]}),
 ('We used 393,453 SNPs from the Affymetrix GeneChip Human Mapping 500K platform, which was used in a recent report of type 2 diabetes association using the same WTCCC type 2 diabetes samples.', {'entities': [(30, 40, 'platform')]}),
 (' Each study participant in GoKinD was genotyped using the Affymetrix SNP Array 5.0.', {'entities': [(58, 68, 'platform')]}),
 ('Genotyping for all GoKinD subjects was conducted on the Affymetrix 5.0 platform.', {'entities': [(56, 66, 'platform')]}),
 (' For the other four GWASs of the discovery set, we performed genotyping using the Affymetrix 6.0 array.', {'entities': [(82, 92, 'platform')]}),
 (' For the other four GWASs of the discovery set, we performed genotyping using the Affymetrix 6.0 array.', {'entities': [(82, 92, 'platform')]}),
 (' As described by , the genotyping platform used was Affymetrix Genome-Wide Human SNP Array 6.0 (Affymetryx Inc.', {'entities': [(52, 62, 'platform')]}),
 (' We used the Affymetrix_®  Genome-Wide Human SNP Array 6.0 to obtain genotypes for TGCT cases.', {'entities': [(13, 23, 'platform')]}),
 (' Controls had been genotyped previously using the Affymetrix_®  Genome-Wide Human SNP Array 6.0 platform and had passed the same genotyping quality measures used for TGCT cases.', {'entities': [(50, 60, 'platform')]}),
 (' The Spearman correlation coefficient between genotype calls obtained from the Affymetrix_®  chip and iPLEX platform for these three markers ranged from 0.96 to 0.', {'entities': [(79, 89, 'platform')]}),
 ('  Genotyping was performed using the Affymetrix 6.0 array and genotypes were called using the Birdsees software.', {'entities': [(37, 47, 'platform')]}),
 (' Genotyping was performed using the Affymetrix 6.0 array and genotypes were called using the Birdsees software.', {'entities': [(36, 46, 'platform')]}),
 (' Jude study were genotyped with either the Affymetrix GeneChip 500K and 100K or 6.0 array.', {'entities': [(43, 53, 'platform')]}),
 ('0 Array (Affymetrix, Santa Clara, USA) was conducted to discover SNPs associated with CAD in the CADomics study (Coronary Artery Disease and Genomics), a case-control study of CAD (2,078 CAD cases and 2,953 controls).', {'entities': [(9, 19, 'platform')]}),
 (' Genotyping was conducted on the Affymetrix Genome-Wide Human SNP 6.0 Array; quality control on sample and SNP level was performed according to standardized criteria.', {'entities': [(33, 43, 'platform')]}),
 (' Genotyping was performed using the Affymetrix GeneChip® Human Mapping 500K array set, as recommended by the manufacturer.', {'entities': [(36, 46, 'platform')]}),
 (' For the other four GWASs of the discovery set, we performed genotyping using the Affymetrix 6.0 array.', {'entities': [(82, 92, 'platform')]}),
 (' For the other four GWASs of the discovery set, we performed genotyping using the Affymetrix 6.0 array.', {'entities': [(82, 92, 'platform')]}),
 (' Publicly available Affymetrix SNP Array 6.0 Chip SNP data were also obtained for the same cell lines.', {'entities': [(20, 30, 'platform')]}),
 (' CAPS samples were genotyped using the Affymetrix 500k gene chip.', {'entities': [(39, 49, 'platform')]}),
 (' For the pooled DNA analysis, the Affymetrix 100K SNP microarray (https://www.', {'entities': [(34, 44, 'platform')]}),
 ('Genotyping in the CARe Consortium was conducted using two chips: the IBC SNP chip () in 7112 AA and 22 539 EA participants, and the Affymetrix 6.0 array in 6089 AA participants.', {'entities': [(132, 142, 'platform')]}),
 (' Principal components were generated using EIGENSTRAT () with the curated CARe African-American Affymetrix 6.0 genotype data combined with 1178 European Americans (EA) (a multiple sclerosis GWAS graciously offered by Dr Phil de Jager and colleagues) and from 756 Nigerians from the Yoruba region (an hypertension GWAS graciously offered by Dr Richard Cooper and colleagues).', {'entities': [(96, 106, 'platform')]}),
 (' Meta-analyses of study-specific results were conducted separately for the Affymetrix 6.0 and the IBC chips using inverse-variance weighted fixed-effect models implemented in METAL ().', {'entities': [(75, 85, 'platform')]}),
 (' For the results from the Affymetrix 6.0 platform, genomic control correction was applied to individual-study results with genomic control factor (λ) >1 prior to meta-analysis.', {'entities': [(26, 36, 'platform')]}),
 ('2) with the reported index SNP in EA individuals (rs606458, rs12800450 and rs493573 in chromosome 11); or (iii) SNPs met region-wide significance in the interrogation of known loci in the Affymetrix 6.0 array GWAS platform and were in low LD (r _2  < 0.', {'entities': [(188, 198, 'platform')]}),
 (' Genotyping in both efforts was performed using the Affymetrix 6.0 array.', {'entities': [(52, 62, 'platform')]}),
 (' Controls for both the GAIN-BP and BiGS samples were ascertained throughout the United States and genotyped on the Affymetrix 6.0 array as part of the Molecular Genetics of Schizophrenia II (MGS2) Collaboration ().', {'entities': [(115, 125, 'platform')]}),
 (' Genotyping in both efforts was performed using the Affymetrix 6.0 array.', {'entities': [(52, 62, 'platform')]}),
 (' Controls for both the GAIN-BP and BiGS samples were ascertained throughout the United States and genotyped on the Affymetrix 6.0 array as part of the Molecular Genetics of Schizophrenia II (MGS2) Collaboration ().', {'entities': [(115, 125, 'platform')]}),
 ('SNP genotyping was conducted using the Affymetrix Genome-wide Human SNP Array 5.0 and quality control was performed, both as previously described [].', {'entities': [(39, 49, 'platform')]}),
 (' Genome-wide genotyping in the FHS was performed on the Affymetrix GeneChip Human Mapping 500K Array Set® and 50K Human Gene Focused Panel®.', {'entities': [(56, 66, 'platform')]}),
 (' Genome-wide genotyping in the FHS was performed on the Affymetrix GeneChip Human Mapping 500K Array Set® and 50K Human Gene Focused Panel®.', {'entities': [(56, 66, 'platform')]}),
 (' Genotyping was performed with the Affymetrix 5.0 SNP chip, which contains probes for 500,568 SNPs.', {'entities': [(35, 45, 'platform')]}),
 (' Genotyping was performed with the Affymetrix 5.0 SNP chip, which contains probes for 500,568 SNPs.', {'entities': [(35, 45, 'platform')]}),
 (' Genotyping was performed at the Center for Inherited Disease Research using 1 μg of genomic DNA (diluted in 1× TE buffer and at 50 ng/μl) on Affymetrix Genome-Wide Human SNP array 6.0.', {'entities': [(142, 152, 'platform')]}),
 ('  Genotypes were assayed using the Affymetrix Genome-Wide Human SNP Array 6.0 platform, and genotypes were called using the Birdseed algorithm.', {'entities': [(35, 45, 'platform')]}),
 (' Genotypes were assayed using the Affymetrix Genome-Wide Human SNP Array 6.0 platform, and genotypes were called using the Birdseed algorithm.', {'entities': [(34, 44, 'platform')]}),
 (' RNA from the tissue biopsies was hybridized to Affymetrix ST 1.0 Exon arrays and obtained scans were RMA normalized and log2 transformed.', {'entities': [(48, 58, 'platform')]}),
 ('Genotyping was conducted at Perlegen Sciences using their 600K genotyping platform, which comprises approximately 600,000 tagging SNPs designed to be in high linkage disequilibrium with untyped SNPs for the three HapMap populations.', {'entities': [(28, 36, 'platform')]})]